

CURRICULUM VITAE

(Last update: September 2026)



Dr. CHRISTOS K. KONTOS

Associate Professor

Table of Contents

	<i>Page</i>
CONTACT INFORMATION	3
CURRENT POSITION	3
PREVIOUS POSITIONS.....	3
DISTINCTIONS & AWARDS	4
A. Awards and Scholarships	4
B. Reviewer of Research Grants in International and National Agencies	4
C. Reviewer in International Peer-Reviewed Scientific Journal upon Personal Invitation	4
D. Other Distinctions	6
ORGANIZING ACTIVITIES & ADMINISTRATIVE WORK	8
A. Participation in the Organization of International Scientific Conferences	8
B. Member of Scientific Societies	8
TEACHING ACTIVITIES & EDUCATIONAL WORK	8
A. Teaching of Undergraduate Courses	8
B. Teaching of Postgraduate Courses	8
C. Supervision of Theses.....	9
D. Other Educational Work.....	9
RESEARCH ACTIVITIES & SCIENTIFIC RECORD	9
A. Research Interests.....	9
B. Participation in Research Grants	10
C. International scientific collaborations	11
D. Scientific Work Metrics	11
E. Participation in Scientific Conferences and Symposia.....	12
E ₁ . Oral Presentations in International Scientific Conferences.....	12
E ₂ . Oral Presentations in National Scientific Conferences	12
E ₃ . Poster Presentations in International Scientific Conferences.....	13
E ₄ . Poster Presentations in National Scientific Conferences	16
F. List of Publications	17
F ₁ . Publications in International, Peer-Reviewed Scientific Journals.....	17
F ₂ . Chapters in International, Peer-Reviewed Scientific Books	28
F ₃ . Abstracts in Proceedings of International Conferences.....	28
F ₄ . Abstracts in Proceedings of National Conferences	40

CONTACT INFORMATION

Name: Dr. Christos K. Kontos

Affiliation: ➤ Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens (N.K.U.A.), Athens, Greece

➤ Institute of Applied Molecular Biology – Biomarkers and Omics Technologies, University Center of Research and Innovation “Antonis Papadakis”, National and Kapodistrian University of Athens, Athens, Greece

➤ Institute of Molecular Typing of Hematological Neoplasms, University Center of Research and Innovation “Antonis Papadakis”, National and Kapodistrian University of Athens, Athens, Greece

Phone numbers: Office: (+30)210-727-4616; Mob.: (+30)697-340-4037

e-mail address: chkontos@biol.uoa.gr

CURRENT POSITION

2026-today *Associate Professor of Molecular Biology*, Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens (N.K.U.A.), Athens, Greece.

2025-today *Principal Investigator*, University Center of Research and Innovation “Antonis Papadakis”, National and Kapodistrian University of Athens (N.K.U.A.), Athens, Greece.

PREVIOUS POSITIONS

2021-2025 *Assistant Professor of Molecular Biology (tenured)*, Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens (N.K.U.A.), Athens, Greece.

2018-2021 *Assistant Professor of Molecular Biology (non-tenured)*, Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens (N.K.U.A.), Athens, Greece.

2015-2018 *Lecturer (non-tenured) of Molecular Biology and Food Biotechnology*, Department of Food Science and Nutrition, University of the Aegean, Lemnos, Greece.

2016-2017 *Academic Scholar of Molecular Biology*, Department of Medicine, Faculty of Health Science, National and Kapodistrian University of Athens (N.K.U.A.), Athens, Greece.

2016 *Postdoctoral Researcher*, Second Department of Internal Medicine and Research Unit, University General Hospital “Attikon”, Athens, Greece.

2011-2015 *Postdoctoral Researcher*, Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens (N.K.U.A.), Athens, Greece.

2010-2011 *Postdoctoral Fellow*, Laboratory of Signal Mediated Gene Expression; Institute of Biology, Medicinal Chemistry and Biotechnology; National Hellenic Research Foundation (N.H.R.F.); Athens, Greece.

2004-2009 *PhD student*, Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens (N.K.U.A.), Athens, Greece.

DISTINCTIONS & AWARDS

A. Awards and Scholarships

- ❖ Award for best presentation in the XIth Eurasian Hematology-Oncology Congress (EHOC), Virtual, 2020.
- ❖ Award for oral presentation in the 30th Congress of the Hellenic Society of Hematology, Athens, 2019.
- ❖ Award for poster presentation in the International Society for Enzymology (ISE) Annual Conference, Syros, Greece, 2016.
- ❖ Second Place Poster Award for a poster presented in the 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK 2013), Toronto, Canada, 2013.
- ❖ Distinguished Abstract Award, given by the National Academy of Clinical Biochemistry, for an abstract in the American Association of Clinical Biochemistry Annual Meeting 2012, Los Angeles, CA, United States, 2012.
- ❖ Scholarship from the National Hellenic Research Foundation (NHRF), Athens, Greece, 2010-2011.
- ❖ Fellowship from the Federation of the Societies of Biochemistry and Molecular Biology (FEBS) for the 34th FEBS Congress “Life’s Molecular Interactions”, Prague, Czech Republic, 2009.
- ❖ Third Place Award, given by the Hellenic Mathematical Society, for excellence in the Greek National Mathematics Contest “Euklides”, Athens, Greece, 1996.
- ❖ Honors Award for 6 consecutive years, given by the National Ministry of Education of Greece, for school excellence, Athens, Greece, 1994-1999.

B. Reviewer of Research Grants in International and National Agencies

- ❖ Invited Reviewer of research grants by the Health Research Board of Ireland.
- ❖ Invited Reviewer of research grants by the Executive Agency for Higher Education, Research, Development and Innovation Funding of Romania.
- ❖ Invited Reviewer of research grants by the National Science Centre (NCN) of Poland.
- ❖ Invited Reviewer of research grants by the Israeli Ministry of Health (Israel).
- ❖ Invited Reviewer of research grants by the Swiss National Science Foundation (SNSF) (Switzerland).
- ❖ Invited Evaluator of research grants, “1st Call for H.F.R.I. research projects to support Postdoctoral Researchers “, Hellenic Foundation for Research and Innovation (H.F.R.I.) of Greece.
- ❖ Invited Reviewer of research grants by the University of Patras (Greece).
- ❖ Invited Reviewer of EU Erasmus+ research grants by the Hellenic National Agency (Greece).

C. Reviewer in International Peer-Reviewed Scientific Journal upon Personal Invitation

- | | |
|--------------------------------|---|
| ❖ Advanced Science | ❖ Frontiers in Cell and Developmental Biology |
| ❖ Advances in Medical Sciences | ❖ Frontiers in Endocrinology |
| ❖ Aging and Disease | ❖ Frontiers in Genetics |
| ❖ Aging-US | ❖ Frontiers in Immunology |
| ❖ Analyst | ❖ Frontiers in Molecular Biosciences |
| ❖ Analytical Biochemistry | ❖ Frontiers in Oncology |
| ❖ Animals | ❖ Frontiers in Pharmacology |

- ❖ Annals of Translational Medicine
- ❖ Anti-Cancer Agents in Medicinal Chemistry
- ❖ Antioxidants
- ❖ Applied Biochemistry and Biotechnology
- ❖ Applied Sciences
- ❖ Arab Journal of Gastroenterology
- ❖ Archiv der Pharmazie
- ❖ Archives of Biochemistry and Biophysics
- ❖ BBA - Gene Regulatory Mechanisms
- ❖ BBA - Reviews on Cancer
- ❖ Biochemical Genetics
- ❖ Biochemistry and Biophysics Reports
- ❖ Bioengineered
- ❖ Biological Chemistry
- ❖ Biology
- ❖ Biomarkers
- ❖ Biomarkers in Medicine
- ❖ BioMed Research International
- ❖ Biomedicine & Pharmacotherapy
- ❖ Biomedicines
- ❖ Biomolecules
- ❖ Biotechniques
- ❖ BMC Cancer
- ❖ BMC Gastroenterology
- ❖ BMC Genomics
- ❖ BMC Medicine
- ❖ BMC Molecular Biology
- ❖ Breast Cancer Research
- ❖ British Journal of Cancer
- ❖ Cancer
- ❖ Cancer Biomarkers
- ❖ Cancer Cell International
- ❖ Cancer Control
- ❖ Cancer Drug Resistance
- ❖ Cancer Informatics
- ❖ Cancer Innovation
- ❖ Cancer Medicine
- ❖ Cancer Research
- ❖ Cancers
- ❖ Carcinogenesis
- ❖ Cell Biochemistry & Function
- ❖ Cell Biology International
- ❖ Cell Cycle
- ❖ Cell Death & Disease
- ❖ Cell Death Discovery
- ❖ Cell Division
- ❖ Cell Stress and Chaperones
- ❖ Cells
- ❖ Cellular & Molecular Biology Letters
- ❖ Frontiers in Surgery
- ❖ Functional & Integrative Genomics
- ❖ Future Oncology
- ❖ Gene
- ❖ Gene Reports
- ❖ Genes
- ❖ Genes & Diseases
- ❖ Genetics and Molecular Biology
- ❖ Heliyon
- ❖ Immunity, Inflammation and Disease
- ❖ Immunology Letters
- ❖ International Immunopharmacology
- ❖ International Journal of Biological Markers
- ❖ International Journal of Cancer
- ❖ International Journal of Environmental Research and Public Health (IJERPH)
- ❖ International Journal of Immunopathology and Pharmacology
- ❖ International Journal of Laboratory Hematology
- ❖ International Journal of Molecular Medicine
- ❖ International Journal of Molecular Sciences
- ❖ International Journal of Oncology
- ❖ International Scholarly Research Notices
- ❖ Journal of Bone Oncology
- ❖ Journal of Cellular and Molecular Medicine
- ❖ Journal of Chemotherapy
- ❖ Journal of Clinical Laboratory Analysis
- ❖ Journal of Clinical Medicine
- ❖ Journal of International Medical Research
- ❖ Journal of Medical & Surgical Pathology
- ❖ Journal of Molecular Medicine
- ❖ Journal of Translational Medicine
- ❖ Journal of Visualized Experiments
- ❖ Laboratory Investigation
- ❖ Letters in Drug Design & Discovery
- ❖ Leukemia
- ❖ Leukemia & Lymphoma
- ❖ Life Sciences
- ❖ Marine Drugs
- ❖ MedComm
- ❖ MedComm-Oncology
- ❖ Medical Science Monitor
- ❖ Metabolic Brain Disease
- ❖ Metabolites
- ❖ Mini Reviews in Medicinal Chemistry
- ❖ Molecular and Cellular Biology
- ❖ Molecular and Clinical Oncology
- ❖ Molecular Cancer
- ❖ Molecular Cancer Therapeutics
- ❖ Molecular Carcinogenesis
- ❖ Molecular Diagnosis & Therapy

- ❖ Cellular & Molecular Life Sciences
- ❖ Cellular and Molecular Biology
- ❖ Cellular and Molecular Neurobiology
- ❖ Cellular Immunology
- ❖ Clinical and Translational Medicine
- ❖ Clinical Biochemistry
- ❖ Clinical Cancer
- ❖ Clinical Chemistry and Laboratory Medicine
- ❖ Clinical Medicine Insights: Oncology
- ❖ Communications Biology
- ❖ Communications Medicine
- ❖ Current Cancer Therapy Reviews
- ❖ Current Oncology
- ❖ Data in Brief
- ❖ Diabetes, Obesity and Metabolism
- ❖ Diagnostics
- ❖ Discover Oncology
- ❖ Disease Markers
- ❖ Drug Development and Industrial Pharmacy
- ❖ Drug Discovery Today
- ❖ EBioMedicine
- ❖ eJHaem
- ❖ Electronic Journal of Biotechnology
- ❖ Epigenetics
- ❖ Epigenomics
- ❖ European Journal of Inflammation
- ❖ European Journal of Pharmacology
- ❖ Experimental and Molecular Pathology
- ❖ Experimental and Therapeutic Medicine
- ❖ Experimental Cell Research
- ❖ Experimental Hematology
- ❖ Expert Opinion on Orphan Drugs
- ❖ Expert Opinion on Therapeutic Targets
- ❖ Expert Review of Molecular Diagnostics
- ❖ Expert Review of Proteomics
- ❖ FEBS Open Bio
- ❖ Frontiers in Bioscience-Landmark
- ❖ Frontiers in Bioscience-Scholar
- ❖ Molecular Genetics & Genomic Medicine
- ❖ Molecular Immunology
- ❖ Molecular Medicine
- ❖ Molecular Medicine Reports
- ❖ Molecular Therapy Oncolytics
- ❖ NAR Cancer
- ❖ Nature Communications
- ❖ Nature Protocols
- ❖ Non-coding RNA
- ❖ Non-coding RNA Research
- ❖ Oncology Letters
- ❖ Oncology Reports
- ❖ Pathology - Research and Practice
- ❖ Pathology & Oncology Research
- ❖ Personalized Medicine
- ❖ Pharmaceuticals
- ❖ Pharmacological Research
- ❖ PLOS Computational Biology
- ❖ PLOS Genetics
- ❖ Plos One
- ❖ Polymers
- ❖ Progress in Biophysics and Molecular Biology
- ❖ RNA Biology
- ❖ Scientific Reports
- ❖ Signal Transduction and Targeted Therapy
- ❖ Technology in Cancer Research & Treatment
- ❖ The International Journal of Biological Markers
- ❖ The Journal of Gene Medicine
- ❖ Theranostics
- ❖ Tissue & Cell
- ❖ Translation Oncology
- ❖ Translational Neuroscience
- ❖ Translational Oncology
- ❖ Tumor Biology
- ❖ World Journal of Clinical Oncology
- ❖ World Journal of Gastroenterology
- ❖ World Journal of Gastrointestinal Oncology
- ❖ World Journal of Surgical Oncology

D. Other Distinctions

- ❖ Triage Editor, upon personal invitation, in international, peer-reviewed, scientific journals:
 - Gene Reports (Elsevier)
- ❖ Associate Editor, upon personal invitation, in international, peer-reviewed, scientific journals:
 - Functional & Integrative Genomics (Springer Nature)
 - Gene Reports (Elsevier)
 - Biochemistry Research International (Wiley)

- ❖ Section Editor, upon personal invitation, in international, peer-reviewed, scientific journals:
 - International Journal of Molecular Sciences (MDPI)
 - Frontiers in Cell Science (Frontiers)
- ❖ Academic Editor, upon personal invitation, in international, peer-reviewed, scientific journals:
 - Cancers (MDPI)
 - Cells (MDPI)
 - International Journal of Molecular Sciences (MDPI)
 - Genes (MDPI)
 - Biomedicines (MDPI)
 - Frontiers in Oncology (Frontiers)
 - BioMed Research International (Hindawi)
 - Oncology Letters (Spandidos Publications)
 - World Journal of Clinical Oncology (BPG)
- ❖ Guest Editor, upon personal invitation, in international, peer-reviewed, scientific journals:
 - Current Drug Targets (Bentham Science Publishers)
 - Frontiers in Cardiovascular Medicine (Frontiers)
 - Frontiers in Cell and Developmental Biology (Frontiers)
 - Frontiers in Endocrinology (Frontiers)
 - Frontiers in Genetics (Frontiers)
 - Frontiers in Immunology (Frontiers)
 - Frontiers in Bioscience-Elite (IMR Press)
 - Frontiers in Bioscience-Landmark (IMR Press)
- ❖ Invited Author in international, peer-reviewed, scientific journals:
 - Genome Biology (2020)
 - Cancers (2020)
 - Biomedicines (2020)
 - Personalized Medicine (2020)
 - EBioMedicine (2015)
 - Austin Journal of Cancer and Clinical Research (2013)
- ❖ Invited Author in the scientific eBook Chapter “Cancer Chemotherapy: Recent Developments” (2015).
- ❖ Session Chair, The 2nd International Electronic Conference on Genes, online, December 2024.
- ❖ Invited Plenary Speaker at the 74th National Conference of the Hellenic Society of Biochemistry and Molecular Biology (HSBMB), Thessaloniki, Greece, December 2024.
- ❖ Invited Speaker at the 2nd Hellenic Conference of Pathophysiology, Athens, Greece, October 2024.
- ❖ Invited Speaker at a Scientific Networking Event organized by CIVIS - A European Civic University, Madrid, Spain, October 2024.
- ❖ Invited Lecturer at CIVIS - A European Civic University “Biochemistry” courses.
- ❖ Invited Speaker at the 21st Conference of the Hellenic Society of Clinical Chemistry – Clinical Biochemistry, Athens, Greece, October 2023.
- ❖ Invited Lecturer at Ludwig Maximilian University (LMU), Munich, Germany, October 2022.
- ❖ Invited Lecturer at the University of Delaware, Newark, DE, United States, October 2021.
- ❖ Invited Speaker at the 8th Conference on Head and Neck Cancer, Sfax, Tunisia, January 2007.

ORGANIZING ACTIVITIES & ADMINISTRATIVE WORK

A. Participation in the Organization of International Scientific Conferences

- ❖ International Society for Enzymology (ISE) Annual Conferences, Greece, 2015-2019, 2021-2024 (Member of the Organizing Committee).
- ❖ INsPiRE: International Conference “Tumour biomarkers: From discovery to clinical applications”, Athens, Greece, 2014 (Member of the Organizing Committee).

B. Member of Scientific Societies

- ❖ Hellenic Society of Biochemistry and Molecular Biology (HSBMB)
- ❖ Hellenic Society of Biological Sciences
- ❖ Hellenic Society of Hematology
- ❖ International Proteolysis Society (IPS)
- ❖ International Society for Enzymology (ISE)

TEACHING ACTIVITIES & EDUCATIONAL WORK

A. Teaching of Undergraduate Courses

- ❖ *Biochemistry*, Faculty of Pharmacy, N.K.U.A. (Academic years: 2022-today).
- ❖ *Molecular Biology*, Faculty of Biology, N.K.U.A. (Academic years: 2017-today).
- ❖ *Advanced courses of Molecular Biology*, Faculty of Biology, N.K.U.A. (Academic years: 2017-today).
- ❖ *Genomics*, Faculty of Biology, N.K.U.A. (Academic years: 2020-today).
- ❖ *History & Evolution of Biology*, Faculty of Biology, N.K.U.A. (Academic years: 2020-2025).
- ❖ *Molecular Biology*, Department of Food Science and Nutrition, University of the Aegean (Academic years: 2015-2018).
- ❖ *Genetics and Nutrition*, Department of Food Science and Nutrition, University of the Aegean (Academic years: 2015-2017).
- ❖ *Food Biotechnology*, Department of Food Science and Nutrition, University of the Aegean (Academic years: 2015-2017).

B. Teaching of Postgraduate Courses

- ❖ *Molecular Diagnostics*, MSc “Clinical Biochemistry – Molecular Diagnostics”, N.K.U.A. (Academic years: 2013-today).
- ❖ *Molecular Background of Human Diseases*, MSc “Clinical Biochemistry – Molecular Diagnostics”, N.K.U.A. (Academic years: 2013-today).
- ❖ *Biostatistics – Bioinformatics*, MSc “Clinical Biochemistry – Molecular Diagnostics”, N.K.U.A. (Academic years: 2014-today).
- ❖ *Pathobiochemistry*, MSc “Clinical Biochemistry – Molecular Diagnostics”, N.K.U.A. (Academic years: 2017-today).
- ❖ *Aging and Disease*, MSc “Applications of Biology in Medicine”, N.K.U.A. (Academic years: 2015-2023).
- ❖ *Architecture of Biological Systems*, MSc “Applications of Biology in Medicine”, N.K.U.A. (Academic years: 2014-today). (Academic years: 2015-2023).

- ❖ *Biology: Theory and Experiment II*, MSc “Modern Trends in the Teaching of Biology with the Aid of New Technologies”, N.K.U.A. (Academic years: 2017-2023).
- ❖ *Genetic Information Flow*, MSc “Modern Trends in the Teaching of Biology with the Aid of New Technologies”, N.K.U.A. (Academic years: 2023-today).
- ❖ *Biological Systems*, MSc “Modern Trends in the Teaching of Biology with the Aid of New Technologies”, N.K.U.A. (Academic years: 2023-today).
- ❖ *Microarray Technologies and Applications*, MSc “Bioinformatics”, N.K.U.A. (Academic years: 2018-today).
- ❖ *Molecular Biology and Genomics*, MSc “Bioinformatics”, N.K.U.A. (Academic years: 2018-today).
- ❖ *The Biotechnology Toolbox*, MSc “Biotechnology”, N.K.U.A. (Academic years: 2021-2022).
- ❖ *Fundamentals of Oncology*, MSc “Surgical Oncology”, N.K.U.A. (Academic year: 2016-2017).
- ❖ MSc “Biomedical Sciences”, University of Patras (Academic year: 2019-2020).

C. Supervision of Theses

- ❖ 5 PhD theses (currently: 3).
- ❖ 16 MSc theses (currently: 2).
- ❖ 34 Diploma theses (currently: 1).

D. Other Educational Work

Translation and editing of 3 chapters of the scientific book «*Lewin's GENES XII*» in Greek:

- ❖ Chapter 21. Catalytic RNA
- ❖ Chapter 29. Noncoding RNA
- ❖ Chapter 30. Regulatory RNA

Invited external examiner of 9 BSc theses of students at the German International University (Cairo, Egypt).

RESEARCH ACTIVITIES & SCIENTIFIC RECORD

A. Research Interests

- Epitranscriptomics: Study of the role of RNA base modifications in human physiology and cancer development progression.
- Transcriptomics: Characterization and study of novel alternative splice variants and study of their role in cancer development progression.
- Discovery and study of novel circular RNAs (circRNAs) and other non-coding RNA (ncRNA) molecules.
- Study of gene expression regulation by microRNAs (miRNAs) and tRNA-derived fragments (tRF, tiRNA) in cancer cells.
- Identification of new molecular tumor biomarkers and therapeutic targets.

B. Participation in Research Grants

1. Elucidation of risk factors and health determinants associated with progression of Monoclonal Gammopathies to Multiple Myeloma. Organization: European Commission (EU. HORIZON EUROPE 2023-2026). EU Coordinator: Prof. M.A. Dimopoulos.
2. Strategic research and innovation program for the development of MU - Plovdiv (SRIPD - MUP). Organization: European Commission (NextGenerationEU, 2025). Coordinator: *Prof. Dr. Angel Uchikov*.
3. Search, isolation, and characterization of novel indigenous lactic acid bacteria for use in the development and production of starter cultures for the dairy industry. Organization: European Union (European Social Fund - ESF) and Operational Program “Attica 2014-2020” (National Strategic Reference Framework – NSRF, 2023-2024). Principal Investigator: Prof. D. Hatzinikolaou.
4. Study of the regulation of pro-apoptotic BAX protein expression by circular RNAs of the same gene and its association with apoptosis induction in B-CLL. Organization: Gilead Sciences Hellas (2023-2024). Principal Investigator: Assist. Prof. C. K. Kontos.
5. Islands on islands: deciphering the unknown biodiversity of Aegean wetlands by innovative molecular methods. Organization: Green Fund (2023-2024). Principal Investigator: Prof. A. Parmakelis.
6. Investigation of the role of alternative pre-mRNA splicing of apoptosis-involved genes in the programmed cell death of human cells. Organization: Hellenic Foundation for Research and Innovation (H.F.R.I., 2022-2024). Principal Investigator: Assist. Prof. C. K. Kontos.
7. Designing and development of innovative molecules, based on bioactive metabolites of *Olea Europaea*, with anti-inflammatory and anti-cancer activity (DDIOL). Organization: European Union (European Social Fund - ESF) and Operational Program “EPAnEK” (National Strategic Reference Framework - NSRF, 2020-2023). Coordinator: Prof. L. Skaltsounis.
8. Non-invasive molecular methodology for diagnosis and post-treatment monitoring of bladder cancer (UroMark). Organization: European Union (European Social Fund - ESF) and Operational Program “EPAnEK” (National Strategic Reference Framework – NSRF, 2020-2023). Coordinator: Prof. A. Scorilas.
9. *Sequencing the transcriptome of Helix aspersa*. Organization: Alexander S. Onassis Public Benefit Foundation (2014-2016). Principal Investigator: Assoc. Prof. A. Parmakelis.
10. *Identification and evaluation of novel BIOMarkers for early diagnosis, PROgnosis, and treatment MONitoring of breast and prostate cancers, through the development of hypersensitive molecular methodologies (BIOPROMO)*. Organization: European Union (European Social Fund - ESF) and Operational Program “Education and Lifelong Learning” (National Strategic Reference Framework - NSRF) (THALES, 2011-2015). Principal Investigator: Prof. A. Scorilas.
11. INtegrating the emerging research Potential of the University of Athens Cancer Research Group in the European research area (INsPiRE). Organization: European Commission (EU. FP7-REGIONS, 2011-2014). EU Coordinator: Prof. C. Kittas.
12. Development of sensitive methodologies for exploitation of early epigenetic marker diagnosis in major types of cancer (EpiDiaCan). Organization: European Commission (EU. FP7-HEALTH, 2010-2012). EU Coordinator: Dr. A. Pintzas.
13. *Understanding the effect of productive processes in ecology of microorganisms that deteriorate/infect dairy products (ESL) and fresh fruit juices – Development of molecular methodologies and mathematical models for the prediction of their lifetime*. Organization: European Regional Development Fund and General Secretary for Research and Technology of Greece (EPAN II, COOPERATION, 2011-2014). Principal Investigator: Prof. A. Scorilas.

14. *Development of a new prognostic and monitoring method of colon and gastric carcinoma.* Organization: European Social Fund and General Secretary for Research and Technology of Greece (PENED 2003, 2005-2009). Principal Investigator: Prof. A. Scorilas.
15. *Expression analysis of L-DOPA Decarboxylase in cancer cells. Study of its differential diagnostic and prognostic value in prostate cancer.* Organization: European Social Fund and Greek Ministry of Education (PYTHAGORAS II, 2005-2008). Principal Investigator: Prof. E.G. Fragoulis.
16. *Development and study of novel molecular biomarkers for diagnosis, prognosis and prediction of therapy response in prostate cancer.* Organization: European Social Fund and General Secretary for Research and Technology of Greece (EPAN E&T Greece-Czech Republic, 2005-2007). Principal Investigator: Prof. A. Scorilas.
17. *Development of a novel molecular method for diagnosis, prognosis, and prediction of therapy response in nasopharyngeal cancer (NPC).* Organization: European Social Fund and General Secretary for Research and Technology of Greece (EPAN E&T Greece-Tunisia, 2005-2007). Principal Investigator: Prof. A. Scorilas.
18. *Expression analysis and study of the role of BCL2L12, a newly identified Bcl-2 family member, in sensitivity versus resistance of tumor cells to death-ligand- and drug-induced apoptosis.* Organization: European Social Fund and General Secretary for Research and Technology of Greece (EPAN E&T Greece-Spain Cooperation, 2002-2005). Principal Investigator: Prof. A. Scorilas.

C. International scientific collaborations

- ❖ Prof. Thomas Carell [Department of Chemistry, Faculty of Chemistry and Pharmacy, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany]
- ❖ Prof. Jérôme Moreaux (Faculté de Médecine, Université de Montpellier, Montpellier, France).
- ❖ Prof. Ioana Berindan-Neagoe (Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania).
- ❖ Prof. Victoria Sarafian (Department of Medical Biology, Medical University of Plovdiv, Plovdiv, Bulgaria).
- ❖ Prof. Maria Kazakova (Department of Medical Biology, Medical University of Plovdiv, Plovdiv, Bulgaria).
- ❖ Associate Prof. Mona Batish (Department of Biological Sciences, University of Delaware, Delaware, DE, U.S.A.).
- ❖ Associate Prof. Nikolay Mehterov (Department of Medical Biology, Medical University of Plovdiv, Plovdiv, Bulgaria).
- ❖ Associate Prof. Jan Trna (Department of Gastroenterology and Internal Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic).
- ❖ Assistant Prof. Rana A. Youness (Biology and Biochemistry Department, Faculty of Biotechnology, German International University, Cairo, Egypt).
- ❖ Dr. Leili Rejali (Shahid Beheshti University of Medical Sciences, Tehran, Iran).

D. Scientific Work Metrics

- ❖ **130** publications in international, peer-reviewed, scientific journals: **93** Original research papers, **5** Letters to the Editor, **20** Reviews, **9** Mini-reviews, **1** Commentary, **2** Editorials.
- ❖ First author of **26** publications; second author of **33** publications; corresponding author of **45** publications.
- ❖ **3** chapters in international, peer-reviewed, scientific books.

- ❖ >1,000 records in GenBank® of NCBI.
- ❖ 9 Gene mini-reviews in *Atlas of Genetics and Cytogenetics in Oncology and Haematology*.
- ❖ **Total Impact Factor = 441.2; Mean Impact Factor = 3.8.**
- ❖ 3,702 citations (*Google Scholar, September 2026*); 2,822 citations by 2,061 documents (*Scopus, September 2026*).
- ❖ **h-index = 36** (*Google Scholar, September 2026*); **h-index = 31** (*Scopus, September 2026*).
- ❖ **i10-index = 95** (*Google Scholar, September 2026*).
- ❖ 271 publications in conference proceedings (of which: 168 publications in international conference proceedings and 103 publications in national conference proceedings).

E. Participation in Scientific Conferences and Symposia

E1. Oral Presentations in International Scientific Conferences

1. 29th International Society for Enzymology (ISE) Annual Conference, Astypalaia, Greece, July 2026.
2. 28th International Society for Enzymology (ISE) Annual Conference, Kefalonia, Greece, July 2025.
3. 27th International Society for Enzymology (ISE) Annual Conference, Milos, Greece, July 2024.
4. 26th International Society for Enzymology (ISE) Annual Conference, Crete, Greece, July 2023.
5. 25th International Society for Enzymology (ISE) Annual Conference, Samos, Greece, July 2022.
6. 24th International Society for Enzymology (ISE) Annual Conference, Virtual, December 2021.
7. 23rd International Society for Enzymology (ISE) Annual Conference, Chios, Greece, July 2019.
8. 4th Symposium on Advances in Cancer Immunology and Immunotherapy, Athens, November-December 2018.
9. 22nd International Society for Enzymology (ISE) Annual Conference, Naxos, Greece, July 2018.
10. 20th International Society for Enzymology (ISE) Annual Conference, Syros, Greece, July 2016.
11. International Conference: Tumour biomarkers: From discovery to clinical applications, Athens, Greece, June 2014.
12. 18th World Congress on Advances in Oncology, *and* 16th International Symposium on Molecular Medicine, Crete, Greece, October 2013.
13. 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK 2013), Toronto, Canada, September-October 2013.
14. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK 2011), Rhodes, Greece, September 2011.
15. 8th Conference on Head and Neck Cancer, Sfax, Tunisia, January 2007 (Invited Plenary Speaker).

E2. Oral Presentations in National Scientific Conferences

1. 36th Congress of the Hellenic Society of Hematology, Athens, November 2025.
2. 74th Conference of the Hellenic Society of Biochemistry and Molecular Biology, Thessaloniki, December 2024.
3. 2nd Hellenic Conference of Pathophysiology, Athens, October 2024.
4. 73rd Conference of the Hellenic Society of Biochemistry and Molecular Biology, Athens, December 2023.
5. 16th Conference of the Hellenic Society of Clinical Chemistry – Clinical Biochemistry, Athens, October 2023.

6. 72nd Conference of the Hellenic Society of Biochemistry and Molecular Biology, Patras, December 2022.
7. 33rd Congress of the Hellenic Society of Hematology, Thessaloniki, November 2022.
8. 71st Conference of the Hellenic Society of Biochemistry and Molecular Biology, Athens, November 2021.
9. 47th Annual Hellenic Medical Congress, Athens, May 2021.
10. 31st Congress of the Hellenic Society of Hematology, Athens, November 2020.
11. 30th Congress of the Hellenic Society of Hematology, Athens, November 2019.
12. 69th Conference of the Hellenic Society of Biochemistry and Molecular Biology, Larissa, November 2018.
13. 29th Congress of the Hellenic Society of Hematology, Thessaloniki, November 2018.
14. 40th Conference of the Hellenic Society of Biological Sciences, Veroia, May 2018.
15. 28th Congress of the Hellenic Society of Hematology, Athens, November 2017.
16. 39th Scientific Conference of the Hellenic Society of Biological Sciences, Lamia, May 2017.
17. 27th Congress of the Hellenic Society of Hematology, Thessaloniki, November 2016.
18. 38th Scientific Conference of the Hellenic Society of Biological Sciences, Kavala, May 2016.
19. 26th Congress of the Hellenic Society of Hematology, Athens, November 2015.
20. 37th Scientific Conference of the Hellenic Society of Biological Sciences, Volos, May 2015.
21. 25th Congress of the Hellenic Society of Hematology, Thessaloniki, November 2014.
22. 12th Annual Congress of the Hellenic Society of Surgical Oncology, Athens, December 2013.
23. 24th Congress of the Hellenic Society of Hematology, Athens, November 2013.
24. 35th Scientific Conference of the Hellenic Society of Biological Sciences, Nafplion, May 2013.
25. 23rd Congress of the Hellenic Society of Hematology, Thessaloniki, November 2012.
26. 22nd Congress of the Hellenic Society of Hematology, Athens, November 2011.
27. 36th Annual Hellenic Medical Congress, Athens, May 2010.

E3. Poster Presentations in International Scientific Conferences

1. 50th FEBS Congress “Biochemistry for the next 50 years”, Maastricht, The Netherlands, July 2026.
2. American Society of Hematology (ASH) 67th Annual Meeting, Orlando, FL, United States, December 2025.
3. 28th International Society for Enzymology (ISE) Annual Conference, Kefalonia, Greece, July 2025.
4. ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, July 2025.
5. 49th FEBS Congress “Bridging Continents to Advance Life Science”, Istanbul, Turkey, July 2025.
6. American Society of Hematology (ASH) 66th Annual Meeting, San Diego, CA, United States, December 2024.
7. 27th International Society for Enzymology (ISE) Annual Conference, Milos, Greece, July 2024.
8. 48th FEBS Congress “Mining biochemistry for human health and well-being”, Tours, France, June-July 2024.
9. 20th International Myeloma Society (IMS) Annual Meeting, Athens, Greece, September 2023.
10. 26th International Society for Enzymology (ISE) Annual Conference, Crete, Greece, July 2023.
11. 47th FEBS Congress “Together in bioscience for a better future”, Tours, France, July 2023.
12. 28th Congress of the European Hematology Association (EHA), Frankfurt, Germany, June 2023.

13. Global Submit of Cancer Frontier 2023, Tokyo, Japan, May 2023.
14. American Society of Hematology (ASH) 64th Annual Meeting, New Orleans, LA, United States, December 2022.
15. 25th International Society for Enzymology (ISE) Annual Conference, Samos, Greece, July 2022.
16. 25th IUBMB, 46th FEBS, and 15th PABMB Congress “The Biochemistry Global Summit”, Lisbon, Portugal, July 2022.
17. 27th Congress of the European Hematology Association (EHA), Vienna, Austria, June 2022.
18. 24th International Society for Enzymology (ISE) Annual Conference, Virtual, December 2021.
19. 45th FEBS Virtual Congress “Molecular of Life: Towards New Horizons”, Ljubljana, Slovenia, July 2021.
20. 26th Congress of the European Hematology Association (EHA), Virtual, June 2021.
21. 2nd Meeting of the European Myeloma Network, Virtual, March 2021.
22. 1st Translational Conference: Chronic Lymphocytic Leukemia, Virtual, November 2020.
23. XIth Eurasian Hematology-Oncology Congress (EHOC), Virtual, October 2020.
24. 6th Aegean Hematology Oncology Symposium (AHOS), Cesme-Izmir, Turkey, October 2019.
25. 8th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK 2019), Prague, Czech Republic, September 2019.
26. 23rd International Society for Enzymology (ISE) Annual Conference, Chios, Greece, July 2019.
27. 15th International Conference on Malignant Lymphoma (ICML), Lugano, Switzerland, June 2019.
28. American Society of Clinical Oncology (ASCO) 55th Annual Meeting, Chicago, IL, United States, May-June 2019.
29. 22th International Society for Enzymology (ISE) Annual Conference, Naxos, Greece, July 2018.
30. American Society of Hematology (ASH) 59th Annual Meeting, Atlanta, GA, United States, December 2017.
31. 2017 CPRIT Innovations in Cancer Prevention and Research Conference, Austin, TX, United States, November 2017.
32. 7th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK 2017), Paris, France, September 2017.
33. 21st International Society for Enzymology (ISE) Annual Conference, Santorini, Greece, June 2017.
34. EuroMedLab 2017, Athens, Greece, June 2017.
35. 13th Congress of the European Association of Dermato Oncology (EADO), Athens, Greece, May 2017.
36. American Society of Hematology (ASH) 58th Annual Meeting, San Diego, CA, United States, December 2016.
37. 41st FEBS Congress “Molecular and Systems Biology for a Better Life”, Ephesus, Turkey, September 2016.
38. 20th International Society for Enzymology (ISE) Annual Conference, Syros, Greece, July 2016.
39. American Society of Hematology (ASH) 57th Annual Meeting, Orlando, FL, United States, December 2015.
40. 8th Euro Global Summit on Cancer Therapy, Valencia, Spain, November 2015.
41. 19th International Society for Enzymology (ISE) Annual Conference, Corfu, Greece, June-July 2015.
42. 21st Congress of the European Hematology Association (EHA), Copenhagen, Italy, June 2016.

43. 12th International Symposium on Myelodysplastic Syndromes, Washington, DC, United States, April-May 2015.
44. 19th World Congress on Advances in Oncology, *and* 17th International Symposium on Molecular Medicine, Athens, Greece, October 2014.
45. 25th tRNA Conference, Kyllini, Greece, October 2014.
46. 18th International Society for Enzymology (ISE) Meeting, Kos, Greece, June 2014.
47. International Conference: Tumour biomarkers: From discovery to clinical applications, Athens, Greece, June 2014.
48. 19th Congress of the European Hematology Association (EHA), Milan, Italy, June 2014.
49. International Workshop: “Cell cycle and natural products”, Athens, Greece, May 2014.
50. International Workshop: “Oncogenic Pathways and Antitumor Responses”, Athens, Greece, April 2014.
51. 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK 2013), Toronto, Canada, September-October 2013.
52. International Workshop: “Ageing and Cancer cell biology: Convergent and divergent molecular mechanisms”, Athens, Greece, June 2013.
53. 18th Congress of the European Hematology Association (EHA), Stockholm, Sweden, June 2013.
54. 12th International Symposium on Myelodysplastic Syndromes, Berlin, Germany, May 2013.
55. American Association for Cancer Research (AACR) 104th Annual Meeting, Washington, DC, United States, April 2013.
56. European Tissue Repair Society (ETRS) 22nd Annual Meeting, Athens, Greece, October 2012.
57. American Association for Clinical Chemistry (AACC) Annual Meeting, Los Angeles, CA, United States, July 2012.
58. 17th Congress of the European Hematology Association (EHA), Amsterdam, The Netherlands, June 2012.
59. American Association for Cancer Research (AACR) 103rd Annual Meeting, Chicago, IL, United States, March-April 2012.
60. American Society of Hematology (ASH) 53rd Annual Meeting, Washington, DC, United States, December 2011.
61. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK 2011), Rhodes, Greece, September 2011.
62. 16th Congress of the European Hematology Association (EHA), London, UK, June 2011.
63. 11th International Symposium on Myelodysplastic Syndromes, Edinburgh, UK, May 2011.
64. American Society of Hematology (ASH) 52nd Annual Meeting, Orlando, FL, United States, December 2010.
65. 3rd International Symposium on Kallikreins and Kallikrein-Related Peptidases (IKS 2009), Munich, Germany, August-September 2009.
66. 34th FEBS Congress “Life’s Molecular Interactions”, Prague, Czech Republic, July 2009.
67. 33rd FEBS Congress & 11th IUBMB Conference “Biochemistry of Cell Regulation”, Athens, Greece, June-July 2008.
68. American Society of Clinical Oncology (ASCO) 44th Annual Meeting, Chicago, IL, United States, May-June 2008.
69. American Association for Cancer Research (AACR) 99th Annual Meeting 2008, San Diego, CA, United States, April 2008.
70. 5th General Meeting of the International Proteolysis Society, Patras, Greece, October 2007.

71. 2nd International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK 2007), Santorini, Greece, October 2007.
72. 5th International Conference on Instrumental Methods of Analysis – Modern Trends and Applications, Patras, Greece, September 2007.
73. 32nd FEBS Congress “Molecular Machines”, Vienna, Austria, July 2007.
74. American Association for Cancer Research (AACR) 98th Annual Meeting, Los Angeles, CA, United States, April 2007.
75. 31st FEBS Congress “Molecules in Health and Disease”, Istanbul, Turkey, June 2006.

E4. Poster Presentations in National Scientific Conferences

1. 75th Conference of the Hellenic Society of Biochemistry and Molecular Biology, Athens, December 2025.
2. 36th Congress of the Hellenic Society of Hematology, Athens, November 2025.
3. 74th Conference of the Hellenic Society of Biochemistry and Molecular Biology, Thessaloniki, December 2024.
4. 73rd Conference of the Hellenic Society of Biochemistry and Molecular Biology, Athens, December 2023.
5. 34th Congress of the Hellenic Society of Hematology, Athens, November 2023.
6. 11th Conference of the Hellenic Ecology Society, Patras, October 2023.
7. 72nd Conference of the Hellenic Society of Biochemistry and Molecular Biology, Patras, December 2022.
8. 71st Conference of the Hellenic Society of Biochemistry and Molecular Biology, Athens, November 2021.
9. 70th Conference of the Hellenic Society of Biochemistry and Molecular Biology, Athens, November 2019.
10. 30th Congress of the Hellenic Society of Hematology, Athens, November 2019.
11. 69th Conference of the Hellenic Society of Biochemistry and Molecular Biology, Larissa, November 2018.
12. 29th Congress of the Hellenic Society of Hematology, Thessaloniki, November 2018.
13. 15th Conference of the Hellenic Society of Clinical Chemistry – Clinical Biochemistry, Alexandroupoli, October 2018.
14. 68th Conference of the Hellenic Society of Biochemistry and Molecular Biology, Athens, November 2017.
15. 28th Congress of the Hellenic Society of Hematology, Athens, November 2017.
16. 67th Conference of the Hellenic Society of Biochemistry and Molecular Biology, Ioannina, November 2016.
17. 27th Congress of the Hellenic Society of Hematology, Thessaloniki, November 2016.
18. 14th Conference of the Hellenic Society of Clinical Chemistry – Clinical Biochemistry, Ioannina, September-October 2016.
19. 66th Conference of the Hellenic Society of Biochemistry and Molecular Biology, Athens, December 2015.
20. 26th Congress of the Hellenic Society of Hematology, Athens, November 2015.
21. 65th Conference of the Hellenic Society of Biochemistry and Molecular Biology, Thessaloniki, November 2014.

22. 25th Congress of the Hellenic Society of Hematology, Thessaloniki, November 2014.
23. 64th Conference of the Hellenic Society of Biochemistry and Molecular Biology, Athens, December 2013.
24. 24th Congress of the Hellenic Society of Hematology, Athens, November 2013.
25. 23rd Congress of the Hellenic Society of Hematology, Thessaloniki, November 2012.
26. 62nd Conference of the Hellenic Society of Biochemistry and Molecular Biology, Athens, December 2011.
27. 22nd Congress of the Hellenic Society of Hematology, Athens, November 2011.
28. 8th Hellenic Congress on Tumor Markers and Targeted Therapy, Athens, November 2010.
29. 9th Conference of the Hellenic Society of Clinical Chemistry – Clinical Biochemistry, Athens, October 2010.
30. 18th Congress of the Hellenic Society of Hematology & 2nd Balkan Day of Hematology, Thessaloniki, November 2007.
31. 2nd Conference on Biosciences, Patras, April 2007.

F. List of Publications

F1. Publications in International, Peer-Reviewed Scientific Journals

Original Research Papers

1. Sotiropoulou CD, **Kontos CK***, Vatsellas G, Pappa V, Scorilas A, Papageorgiou SG. Deciphering *BAX* and *BCL2L12* circRNAs in Acute Myeloid Leukemia Through an Integrated Next-Generation and Nanopore Sequencing Approach. *Genes (Basel)*. 2026; 17(8):915 (I.F.=2.8).
*Corresponding Author.
2. Stafyla VK, Christodoulou S, Tsiakanikas P, Michalopoulos N, Danias N, Kokoropoulos P, **Kontos CK***, Arkadopoulos N. Upregulation of a Circular *BAX* Transcript in Breast Cancer Is Associated with Unfavorable Prognosis. *Int J Mol Sci*. 2026; 27(10):4160, (I.F.=4.9).
*Corresponding Author.
3. Katsaraki K, Stafyla VK, Sideris DC, Scorilas A, **Kontos CK***. Discovery of novel circular RNAs of the apoptosis-related *BAX* gene in breast cancer, by combining nanopore and next-generation sequencing. *Funct Integr Genomics*. 2026; 26(1):73, (I.F.=3.9).
*Corresponding Author.
4. Katsaraki K, Vatsellas G, **Kontos CK***. Discovery of novel circular RNAs of the apoptosis-related *BAX* gene in breast cancer, by combining nanopore and next-generation sequencing. *Mol Genet Genomics*. 2026; 301(1):72, (I.F.=2.3).
*Corresponding Author.
5. Papatsirou M, Mavrogonatou E, Kletsas D, Scorilas A, **Kontos CK***. Time- and dose-dependent regulation of circular RNAs in the response of triple-negative breast cancer cells to ionizing radiation. *Clin Transl Oncol*. 2026; 28(8):3180, (I.F.=2.8).
*Corresponding Author.
6. Kokoropoulos P, Christodoulou S, Tsiakanikas P, Poullos E, Vassiliu P, **Kontos CK***, Arkadopoulos N. A Retrospective Study in Colorectal Adenocarcinoma Uncovers the Potential of Circ-CCT3 as a Predictor of Tumor Recurrence. *Biomedicines*. 2025; 13(10):2432, (I.F.=3.9).
*Corresponding Author.

7. Kokoropoulos P, Christodoulou S, Tsiakanikas P, Vassiliu P, **Kontos CK***, Arkadopoulos N. Overexpression of Circular PRMT1 Transcripts in Colorectal Adenocarcinoma Predicts Recurrence and Poor Overall Survival. *Int J Mol Sci.* 2025; 26(14):6683, (I.F.=4.9).
*Corresponding Author.
8. Karousi P, **Kontos CK****, Nikou ST, Carell T, Sideris DC, Scorilas A. Discovery of circular transcripts of the human BCL2-like 12 (*BCL2L12*) apoptosis-related gene, using targeted nanopore sequencing, provides new insights into circular RNA biology. *Funct Integr Genomics.* 2025; 25(1):66, (I.F.=3.9).
*Equal Contributors. **Corresponding Author.
9. Papatsirou M, **Kontos CK***, Ntanasis-Stathopoulos I, Malandrakis P, Theodorakakou F, Liacos CI, Mavrianou-Koutsoukou N, Fotiou D, Migkou M, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Scorilas A, Terpos E*. ciRS-7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myeloma. *EJHaem.* 2024; 5(4):677.
*Corresponding Authors.
10. Bouchla A, Sotiropoulou CD, Esteb C, Loupis T, Papageorgiou SG, Deliconstantinos GG, Pagoni M, Hatzimichael E, Dellatola M, Kalomoiri S, Apostolidou E, **Kontos CK**, Thomopoulos TP, Karantanos T, Pappa V. Silencing of the DNA damage repair regulator PPP1R15A sensitizes acute myeloid leukemia cells to chemotherapy. *Ann Hematol.* 2024; 103(8):2853, (I.F.=3.0).
11. Papatsirou M, **Kontos CK***, Ntanasis-Stathopoulos I, Malandrakis P, Sideris DC, Fotiou D, Liacos CI, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Scorilas A, Terpos E*. Exploring the Molecular Biomarker Utility of circCCT3 in Multiple Myeloma: A Favorable Prognostic Indicator, Particularly for R-ISS II Patients. *Hemasphere.* 2024; 8(1):e34, (I.F.=7.6).
*Corresponding Authors.
12. Diamantopoulos MA, Georgoulia KK, Levis P, Kotronopoulos G, Stravodimos K, **Kontos CK**, Avgeris M, Scorilas A. 28S rRNA-derived Fragments Represent an Independent Molecular Predictor of Short-Term Relapse in Prostate Cancer. *Int J Mol Sci.* 2024; 25(1):239, (I.F.=4.9).
13. Katsaraki K, **Kontos CK***, Ardavanis-Loukeris G, Tzovaras AA, Sideris DC, Scorilas A. Exploring the time-dependent regulatory potential of microRNAs in breast cancer cells treated with proteasome inhibitors. *Clin Transl Oncol.* 2023; 26(5):1256, (I.F.=2.8).
*Corresponding Author.
14. Karousi P, Samiotaki M, Makridakis M, Zoidakis J, Sideris DC, Scorilas A, Carell T, **Kontos CK***. 3'-tRF-Cys^{GCA} overexpression in HEK-293 cells alters the global expression profile and modulates cellular processes and pathways. *Funct Integr Genomics.* 2023; 23(4):341, (I.F.=3.9).
*Corresponding Author.
15. **Kontos CK***, Hadjichambi D, Papatsirou M, Karousi P, Christodoulou S, Sideris DC, Scorilas A. Discovery and Comprehensive Characterization of Novel Circular RNAs of the Apoptosis-Related *BOK* Gene in Human Ovarian and Prostate Cancer Cells, Using Nanopore Sequencing. *Noncoding RNA.* 2023; 9(5):57, (I.F.=3.6).
*Corresponding Author.
16. Karousi P, **Kontos CK***, Papakotsi P, Kostakis IK, Skaltsounis AL, Scorilas A*. Next-generation sequencing reveals altered gene expression and enriched pathways in triple-negative breast cancer cells treated with oleuropein and oleocanthal. *Funct Integr Genomics.* 2023; 23(4):299, (I.F.=3.9).
*Corresponding Authors.
17. **Kontos CK***, Karousi P, Artemaki PI, Abdelgawad A, Dimitriadou A, Machairas NP, Sideris DC, Pappa V, Scorilas A, Batish M, Papageorgiou SG. Novel circular RNAs of the apoptosis-related *BAX* and *BCL2L12* genes identified in a chronic lymphocytic leukemia cell line using nanopore sequencing. *FEBS Open Bio.* 2023; 13(10):1953-1966, (I.F.=2.8).
*Corresponding Author.

18. Sklirou AD, Gianniou DD, Karousi P, Cheimonidi C, Papachristopoulou G, **Kontos CK**, Scorilas A, Trougkos IP. High mRNA Expression Levels of Heat Shock Protein Family B Member 2 (*HSPB2*) Are Associated with Breast Cancer Patients' Relapse and Poor Survival. *Int J Mol Sci*. 2022; 23(17):9758, (I.F.=4.9).
19. Papatsirou M, Diamantopoulos MA, Katsaraki K, Kletsas D, **Kontos CK***, Scorilas A. Identification of Novel Circular RNAs of the Human Protein Arginine Methyltransferase 1 (*PRMT1*) Gene, Expressed in Breast Cancer Cells. *Genes (Basel)*. 2022; 13(7):1133, (I.F.=2.8).
*Corresponding Author.
20. Tsiakanikas P, Adamopoulos PG, Tsiirba D, Artemaki PI, Papadopoulos IN, **Kontos CK***, Scorilas A*. High Expression of a tRNA^{Pro} Derivative Associates with Poor Survival and Independently Predicts Colorectal Cancer Recurrence. *Biomedicines*. 2022; 12; 10(5):1120, (I.F.=3.9).
*Corresponding Authors.
21. Karousi P, Papanota AM, Artemaki PI, Liacos CI, Patseas D, Mavrianou-Koutsoukou N, Liosi AA, Kalioraki MA, Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Scorilas A, Terpos E*, **Kontos CK***. tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature. *Biomedicines*. 2021; 9(12):1811, (I.F.=3.9).
*Corresponding Authors.
22. Papanota AM, Karousi P, **Kontos CK**, Artemaki PI, Liacos CI, Papadimitriou MA, Bagratuni T, Eleutherakis-Papaikovou E, Malandrakis P, Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Avgeris M, Dimopoulos MA, Scorilas A, Terpos E. A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. *Int J Mol Sci*. 2021; 22(23):13144, (I.F.=4.9).
23. Papanota AM, Tsiakanikas P, **Kontos CK**, Malandrakis P, Liacos CI, Ntanasis-Stathopoulos I, Kanellias N, Gavriatopoulou M, Kastritis E, Avgeris M, Dimopoulos MA, Scorilas A, Terpos E. A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. *Cancers*. 2021; 13(15):3877, (I.F.=4.5).
24. Grafanaki K, Skeparnias I, **Kontos CK**, Anastasakis D, Korfiati A, Kyriakopoulos G, Theofilatos K, Mavroudi S, Magoulas G, Papaioannou D, Scorilas A, Stathopoulos C, Drinas D. Pharmacoeypigenomics circuits induced by a novel retinoid-polyamine conjugate in human immortalized keratinocytes. *Pharmacogenomics J*. 2021; 21(6):638-648, (I.F.=2.9).
25. Katsaraki K, Adamopoulos PG, Papageorgiou SG, Pappa V, Scorilas A, **Kontos CK***. A 3' tRNA-derived fragment produced by tRNA^{LeuAAG} and tRNA^{LeuTAG} is associated with poor prognosis in B-cell chronic lymphocytic leukemia, independently of classical prognostic factors. *Eur J Haematol*. 2021; 106(6):821, (I.F.=2.3).
*Corresponding Author.
26. Papatsirou M, Adamopoulos PG, Artemaki PI, Georganti VP, Scorilas A, Vassilacopoulou D, **Kontos CK***. Next-generation sequencing reveals alternative *L*-DOPA decarboxylase (*DDC*) splice variants bearing novel exons, in human hepatocellular and lung cancer cells. *Gene*. 2021; 768:145262 (I.F.=2.6).
*Corresponding Author.
27. Karousi P, Artemaki PI, Sotiropoulou CD, Christodoulou S, Scorilas A, **Kontos CK***. Identification of two novel circular RNAs deriving from *BCL2L12* and investigation of their potential value as a molecular signature in colorectal cancer. *Int J Mol Sci*. 2020; 21(22):8867, (I.F.=4.9).
*Corresponding Author.
28. Artemaki PI, Papatsirou M, Boti MA, Adamopoulos PG, Christodoulou S, Vassilacopoulou D, Scorilas A, **Kontos CK***. Revised exon structure of *L*-DOPA decarboxylase (*DDC*) reveals novel splice variants associated with colorectal cancer progression. *Int J Mol Sci*. 2020; 21(22):8568, (I.F.=4.9).
*Corresponding Author.

29. Skeparnias I, Anastasakis D, Grafanaki K, Kyriakopoulos G, Alexopoulos P, Dougenis D, Scorilas A, **Kontos CK**, Stathopoulos C. Contribution of miRNAs, tRNAs and tRFs to aberrant signaling and translation deregulation in lung cancer. *Cancers*. 2020; 12(10):3056, (I.F.=4.5).
 30. Zisi Z, Adamopoulos PG, **Kontos CK**, Scorilas A. Identification and expression analysis of novel splice variants of the human carcinoembryonic antigen-related cell adhesion molecule 19 (*CEACAM19*) gene using a high-throughput sequencing approach. *Genomics*. 2020; 112(6):4268-4276, (I.F.=3.4).
 31. Nikcevic G, Srzentic Drazilov S, Karan Djurasevic T, Tosic N, **Kontos CK**, Scorilas A, Pavlovic ST. Complex transcriptional regulation of the *BCL2L12* gene: novel, active promoter in K562 cells. *Gene*. 2020; 750:144723, (I.F.=2.6).
 32. Adamopoulos PG, Koukouzeli FE, **Kontos CK**, Scorilas A. Identification of six novel alternative transcripts of the human kallikrein-related peptidase 15 (*KLK15*), using 3'RACE and high-throughput sequencing. *Gene*. 2020; 749:144708, (I.F.=2.6).
 33. Adamopoulos PG, **Kontos CK**, Scorilas A, Sideris DC. Identification of novel alternative transcripts of the human Ribonuclease κ (*RNASEK*) gene using 3' RACE and high-throughput sequencing approaches. *Genomics*. 2020; 112(4):943-951, (I.F.=3.4).
 34. Karousi P, Adamopoulos PG, Papageorgiou SG, Pappa V, Scorilas A, **Kontos CK***. A novel, mitochondrial, internal tRNA-derived RNA fragment possesses clinical utility as a molecular prognostic biomarker in chronic lymphocytic leukemia. *Clin Biochem*. 2020; 85:20-6, (I.F.=2.5).
- *Corresponding Author.
35. Kalioraki MA, Artemaki PI, Sklirou A, **Kontos CK**, Adamopoulos PG, Papadopoulos IN, Trougakos IP, Scorilas A. Heat shock protein beta 3 (*HSPB3*) is an unfavorable molecular biomarker in colorectal adenocarcinoma. *Mol Carcinog*. 2020; 59(1):116-125, (I.F.=3.0).
 36. Artemaki PI, Sklirou A, **Kontos CK**, Liosi AA, Gianniou DD, Papadopoulos IN, Trougakos IP, Scorilas A. High *Clusterin* (*CLU*) mRNA expression levels in tumors of colorectal cancer patients predict a poor prognostic outcome. *Clin Biochem*. 2020; 75:62-69, (I.F.=2.5).
 37. Katsaraki K, Artemaki PI, Papageorgiou SG, Pappa V, Scorilas A, **Kontos CK***. Identification of a novel, internal tRNA-derived RNA fragment as a new prognostic biomarker in chronic lymphocytic leukemia, using an innovative quantitative real-time PCR assay. *Leuk Res*. 2019; 87:106234, (I.F.=2.1).
- *Corresponding Author.
38. Adamopoulos PG, Tsiakanikas P, **Kontos CK**, Panagiotou A, Vassilacopoulou D, Scorilas A. Identification of novel alternative splice variants of the human L-DOPA decarboxylase (*DDC*) gene in human cancer cells, using high-throughput sequencing approaches. *Gene*. 2019; 719:144075 (I.F.=2.6).
 39. Adamopoulos PG, Mavrogiannis AV, **Kontos CK**, Scorilas A. Novel alternative splice variants of the human protein arginine methyltransferase 1 (*PRMT1*) gene, discovered using next-generation sequencing. *Gene*. 2019; 699: 135-144, (I.F.=2.6).
 40. Christodoulou MI, Avgeris M, Kokkinopoulou IK, Maratou E, Mitrou P, **Kontos CK**, Pappas E, Boutati E, Scorilas A, Raptis SG, Fragoulis EG. Blood-based analysis of type-2 diabetes mellitus susceptibility genes identifies specific transcript variants with deregulated expression and association with disease risk. *Sci Rep*. 2019; 9(1):1512-1525, (I.F.=3.8).
 41. Adamopoulos PG, **Kontos CK**, Scorilas A. Discovery of novel transcripts of the human tissue kallikrein (*KLK1*) and kallikrein-related peptidase 2 (*KLK2*) in human cancer cells, exploiting Next-Generation Sequencing technology. *Genomics*. 2019; 111(4):642-652, (I.F.=3.4).
 42. Giotakis AI, Lazaris AC, Kataki A, **Kontos CK**, Giotakis EI. Positive BCL2L12 expression predicts favorable prognosis in patients with laryngeal squamous cell carcinoma. *Cancer Biomark*. 2019; 25(2):141-149, (I.F.=2.2).

43. Diamantopoulos PT, Kotsianidis I, Symeonidis A, Pappa V, Galanopoulos A, Gogos D, Karakatsanis S, Papadaki H, Palla A, Hatzimichael E, Dimou M, Papageorgiou S, Delimpasis S, Papaioannou M, Papoutselis M, Kourakli A, Tsokanas D, Anagnostopoulos A, **Kontos CK**, Panayiotidis P, Viniou NA, Hellenic MDS study group. Chronic myelomonocytic leukemia treated with 5-azacytidine – results from the Hellenic 5-azacytidine Registry. Proposal of a new risk stratification system. *Leuk Lymphoma*. 2019; 60(7):1721-1730, (I.F.=2.2).
44. Papageorgiou SG, Vasilatou D, **Kontos CK**, Kotsianidis I, Symeonidis A, Galanopoulos A, Hatzimichail E, Megalakaki A, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki E, Mparmparousi D, Bouronikou E, Panayiotidis P, Viniou N, Pappa V. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine. A retrospective analysis of the Hellenic (Greek) MDS Study Group. *Amer J Hematol*. 2018; 93(7): 895-901, (I.F.=10.1).
45. Adamopoulos PG*, **Kontos CK***, Diamantopoulos MA, Scorilas A. Molecular cloning of novel transcripts of the adaptor-related protein complex 2 alpha 1 subunit (*AP2A1*) gene, using Next-Generation Sequencing. *Gene*. 2018; 678: 55-64, (I.F.=2.6).
*Equal Contributors.
46. **Kontos CK***, Avgeris M, Vassilacopoulou D, Ardavanis A, Scorilas A. Molecular effects of treatment of human colorectal cancer cells with natural and classical chemotherapeutic drugs: alterations in the expression of apoptosis-related BCL2 family members, including *BCL2L12*. *Curr Pharm Biotechnol*. 2018; 19(13):1064-1075, (I.F.=2.2).
*Corresponding Author.
47. Mavrogiannis AV, Kokkinopoulou I, **Kontos CK**, Sideris DC. Effect of vinca alkaloids on the expression levels of microRNAs targeting apoptosis-related genes in breast cancer cell lines. *Curr Pharm Biotechnol*. 2018; 19(13):1076-1086, (I.F.=2.2).
48. Avgeris M, Stamati L, **Kontos CK**, Piatopoulou D, Marmarinos A, Xagorari M, Baka M, Doganis D, Kosmidis H, Gourgiotis D, Scorilas A. BCL2L12 improves risk-stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia. *Clin Chem Lab Med*. 2018; 56(12): 2104-2118, (I.F.=3.8).
49. Papageorgiou SG, Diamantopoulos MA*, **Kontos CK***, Bouchla A, Vasilatou D, Bazani E, Scorilas A, Pappa V. MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia. *Leuk Lymphoma*. 2019; 60(3):658-667, (I.F.=2.2).
*Equal Contributors.
50. Adamopoulos PG, **Kontos CK**, Scorilas A. Novel splice variants of the human kallikrein-related peptidases 11 (*KLK11*) and 12 (*KLK12*), unraveled by next-generation sequencing technology. *Biol Chem*. 2018; 399(9): 155-65, (I.F.=2.9).
51. Adamopoulos PG, Raptis GD, **Kontos CK**, Scorilas A. Discovery and expression analysis of novel transcripts of the human SR-related CTD associated factor 1 (*SCAF1*) gene in human cancer cells using Next-Generation Sequencing. *Gene*. 2018; 670: 155-65, (I.F.=2.6).
52. Papageorgiou SG*, **Kontos CK***, Tsiakanikas P, Stavroulaki G, Bouchla A, Vasilatou D, Bazani E, Lazarakou A, Scorilas A, Pappa V. Elevated miR-20b-5p expression in peripheral blood mononuclear cells: a novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia. *Leuk Res*. 2018; 70: 1-7, (I.F.=2.1).
*Equal Contributors.
53. Tsiakanikas P, **Kontos CK**, Kerimis D, Papadopoulos IN, Scorilas A. High microRNA-28-5p expression in colorectal adenocarcinoma predicts short-term relapse of node-negative patients and poor overall survival of patients with non-metastatic disease. *Clin Chem Lab Med*. 2018; 56(6): 990-1000, (I.F.=3.8).

54. Gardikas N, Vikentiou M, Konsta E, **Kontos CK**, Papageorgiou SG, Spathis A, Bazani E, Bouchla A, Kapsimali V, Psarra K, Foukas P, Dimitriadis G, Pappa V. Immunophenotypic profile of CD34+ subpopulations and their role in the diagnosis and prognosis of patients with *de-novo*, particularly low-grade myelodysplastic syndromes. *Cytometry B Clin Cytom.* 2018; 96(1):73-82, (I.F.=2.3).
 55. Papageorgiou SG, **Kontos CK**, Kotsianidis I , Vasilatou D , Symeonidis A , Galanopoulos A , Bouchla A , Hatzimichael E , Repousis P , Zikos P , Viniou N , Poulakidas E , Vassilakopoulos TP, Diamantopoulos P , Diamantopoulos MA, Mparmparousi D , Bouronikou E , Papadaki H , Panayiotidis P , Pappa V. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-Azacytidine. A retrospective analysis of the Hellenic (Greek) MDS Study Group. *Hematol Oncol.* 2018; 36(4): 693-700, (I.F.=3.3).
 56. Papageorgiou SG*, **Kontos CK****, Diamantopoulos MA, Bouchla A, Glezou E, Bazani E, Pappa V, Scorilas A. MicroRNA-155-5p overexpression in peripheral blood mononuclear cells of chronic lymphocytic leukemia patients is a novel, independent molecular biomarker of poor prognosis. *Dis Markers.* 2017; 2017:2046545.
- *Equal Contributors. **Corresponding Author.
57. Adamopoulos PG, **Kontos CK**, Scorilas A. Molecular cloning of novel transcripts of human kallikrein-related peptidases 5, 6, 7, 8 and 9 (*KLK5 – KLK9*), using Next-generation sequencing. *Sci Rep.* 2017; 7(1): 17299-17312, (I.F.=3.8).
 58. Parmakelis A, Kotsakiozi P, **Kontos CK**, Adamopoulos PG, Scorilas A. The transcriptome of a “sleeping” invader – *de novo* assembly and annotation of the transcriptome of aestivating *Cornu aspersum*. *BMC Genomics.* 2017; 18(1): 491-8, (I.F.=3.5).
 59. Rapti SM, **Kontos CK**, Christodoulou S, Papadopoulos IN, Scorilas A. miR-34a overexpression predicts poor prognostic outcome in colorectal adenocarcinoma, independently of clinicopathological factors with established prognostic value. *Clin Biochem.* 2017; 50(16-17): 918-24, (I.F.=2.5).
 60. Adamopoulos PG, **Kontos CK**, Scorilas A. Identification and molecular cloning of novel transcripts of the human kallikrein-related peptidase 10 (*KLK10*) gene using next-generation sequencing. *Biochem Biophys Res Commun.* 2017; 487(4): 776-81, (I.F.=2.5).
 61. **Kontos CK**, Tsiakanikas P, Avgeris M, Papadopoulos IN, Scorilas A. miR-15a-5p, a novel prognostic biomarker, predicting recurrent colorectal adenocarcinoma. *Mol Diagn Ther.* 2017; 21(4): 453-464, (I.F.=4.1).
 62. **Kontos CK**, Papageorgiou SG, Diamantopoulos MA, Scorilas A, Bazani E, Vasilatou D, Gkontopoulos K, Glezou E, Stavroulaki G, Dimitriadis G, Pappa V. mRNA overexpression of the hypoxia inducible factor 1 alpha subunit gene (*HIF1A*): an independent predictor of poor overall survival in chronic lymphocytic leukemia. *Leuk Res.* 2017; 53: 65-73, (I.F.=2.1).
 63. Kerimis D, **Kontos CK**, Christodoulou S, Papadopoulos IN, Scorilas A. Elevated expression of miR-24-3p is a potentially adverse prognostic factor in colorectal adenocarcinoma. *Clin Biochem.* 2017; 50(6): 285-92, (I.F.=2.5).
 64. Diamantopoulos MA, **Kontos CK**, Kerimis D, Papadopoulos IN, Scorilas A. Upregulated miR-16 expression is an independent indicator of relapse and poor overall survival of colorectal adenocarcinoma patients. *Clin Chem Lab Med.* 2017; 55(5): 737-47, (I.F.=3.8).
 65. Mpakou VE, Ioannidou H, Konsta E, Vikentiou M, Spathis A, Kontsioti F, **Kontos CK**, Velentzas AD, Papageorgiou S, Vasilatou D, Gontopoulos K, Glezou I, Stavroulaki G, Mpazani E, Kokkori S, Kyriakou E, Karakitsos P, Dimitriadis G, Pappa V. Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia. *Leuk Res.* 2017; 60: 74-81, (I.F.=2.1).
 66. Rapti SM, **Kontos CK**, Papadopoulos IN, Scorilas A. High miR-96 levels in colorectal adenocarcinoma predict poor prognosis, particularly in patients without distant metastasis. *Tumor Biol.* 2016; 37(9): 11815-24.

67. Giotakis AI, **Kontos CK**, Scorilas A. High *BAX/BCL2* mRNA ratio predicts favorable prognosis in laryngeal squamous cell carcinoma, particularly in patients with negative lymph nodes at the time of diagnosis. *Clin Biochem.* 2016; 49(12): 890-6, (I.F.=2.5).
68. Adamopoulos PG, **Kontos CK**, Tsiakanikas P, Scorilas A. Identification of novel alternative splice variants of the *BCL2L12* gene in human cancer cells using next-generation sequencing methodology. *Cancer Lett.* 2016; 373(1): 119-29, (I.F.=9.1).
69. Miltiades P, Lamprianidou E, Vassilakopoulos TP, Papageorgiou SG, Galanopoulos A, **Kontos CK**, Adamopoulos PG, Nakou E, Vakalopoulou S, Garypidou V, Papaioannou M, Hatjiharissi E, Papadaki HA, Spanoudakis E, Pappa V, Scorilas A, Tsatalas C, Kotsianidis I. The Stat3/5 signaling biosignature in hematopoietic stem/progenitor cells predicts response and outcome in myelodysplastic syndrome patients treated with azacitidine. *Clin Cancer Res.* 2016; 22(8): 1958-68, (I.F.=10.0).
70. Skourti E, Logotheti S, **Kontos CK**, Pavlopoulou A, Dimoragka PT, Trougakos IP, Gorgoulis V, Scorilas A, Michalopoulos I, Zoumpourlis V. Progression of mouse skin carcinogenesis is associated with the orchestrated deregulation of mir-200 family members, mir-205 and their common targets. *Mol Carcinog.* 2016; 55(8): 1229-42, (I.F.=3.0).
71. Vassilakopoulou M, Avgeris M, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, **Kontos CK**, Giotakis AI, Scorilas A, Rimm DL, Sasaki CT, Fountzilias G, Psyrri A. Evaluation of PD-L1 expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. *Clin Cancer Res.* 2016; 22(3): 704-13, (I.F.=10.0).
72. **Kontos CK**, Adamopoulos PG, Papageorgiou SG, Pappa V, Scorilas A. mRNA overexpression of kallikrein-related peptidase 14 (*KLK14*) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients. *Clin Chem Lab Med.* 2016; 54(2): 315-24, (I.F.=3.8).
73. Tarushi A, Raptopoulou C, Psycharis V, **Kontos CK**, Kessissoglou D, Tangoulis V, Scorilas A, Psomas G. Copper(II) inverse-[9-metallacrown-3] compounds accommodating diclofenac: structure, magnetism, interaction with biomolecules and cytotoxicity studies. *Eur J Inorg Chem.* 2016; 2016(2): 219-31, (I.F.=2.2).
74. Adamopoulos PG, **Kontos CK**, Papageorgiou SG, Pappa V, Scorilas A. *KLKB1* mRNA overexpression: A novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia. *Clin Biochem.* 2015; 48(13-14): 849-54, (I.F.=2.5).
75. Adamopoulos PG, **Kontos CK**, Rapti SM, Papadopoulos IN, Scorilas A. miR-224 overexpression is a strong and independent prognosticator of short-term relapse and poor overall survival in colorectal adenocarcinoma. *Int J Oncol.* 2015; 46(2): 849-859, (I.F.=4.5).
76. Alexopoulou DK, **Kontos CK**, Christodoulou S, Papadopoulos IN, Scorilas A. *KLK11* mRNA expression predicts poor disease-free and overall survival in colorectal adenocarcinoma patients. *Biomark Med.* 2014; 8(5): 671-85, (I.F.=1.9).
77. Foteinou E, **Kontos CK**, Giotakis AI, Scorilas A. Low mRNA expression levels of kallikrein-related peptidase 4 (*KLK4*) predict short-term relapse in patients with laryngeal squamous cell carcinoma. *Biol Chem.* 2014; 395(9): 1051-62, (I.F.=2.9).
78. Rapti SM, **Kontos CK**, Papadopoulos IN, Scorilas A. Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients. *Clin Chem Lab Med.* 2014; 52(8): 1217-27, (I.F.=3.8).
79. Christodoulou S, Alexopoulou DK, **Kontos CK**, Scorilas A, Papadopoulos IN. Kallikrein-related peptidase-6 (*KLK6*) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma. *Tumor Biol.* 2014; 35(5): 4673-85.
80. Ferraro A, **Kontos CK**, Boni T, Bantounas I, Siakouli D, Kosmidou V, Vlassi M, Spyridakis Y, Tsipras I, Zografos G, Pintzas A. Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three-gene network (miR-21-ITGB4-PCDC4) as predictor of metastatic tumor potential. *Epigenetics.* 2014; 9(1): 129-141, (I.F.=2.9).

81. Kefala M, Papageorgiou SG, **Kontos CK**, Economopoulou P, Tsanas A, Pappa V, Patsouris E, Panayiotides IG, Gorgoulis VG, Foukas PG. Increased expression of phosphorylated NBS1, a key molecule of the DNA damage response machinery, is an adverse prognostic factor in patients with *de novo* myelodysplastic syndromes. *Leuk Res.* 2013; 37(3): 1576-82, (I.F.=2.1).
82. **Kontos CK**, Fendri A, Abdelmajid K, Mokdad-Gargouri R, Scorilas A. Quantitative expression analysis and prognostic significance of the BCL2-associated X gene in nasopharyngeal carcinoma: a retrospective cohort study. *BMC Cancer.* 2013; 13(1): 293-303, (I.F.=3.4).
83. Vasilatou D, Papageorgiou SG, Kontsioti F, **Kontos CK**, Tsiotra P, Mpakou V, Pavlou MAS, Economopoulou C, Dimitriadis G, Dervenoulas J, Pappa V. Expression analysis of mir-17-5p, mir-20a and let-7a microRNAs and their target proteins in CD34+ bone marrow cells of patients with myelodysplastic syndromes. *Leuk Res.* 2013; 37(3): 251-8, (I.F.=2.1).
84. **Kontos CK**, Chantzis D, Papadopoulos IN, Scorilas A. Kallikrein-related peptidase 4 (*KLK4*) mRNA predicts short-term relapse in colorectal adenocarcinoma patients. *Cancer Lett.* 2013; 330(1): 106-12, (I.F.=9.1).
85. Geomela PA, **Kontos CK**, Yiotakis I, Fragoulis EG, Scorilas A. *L*-DOPA decarboxylase mRNA expression is associated with tumor stage and size in head and neck squamous cell carcinoma: a retrospective cohort study. *BMC Cancer.* 2012; 12(1): 484, (I.F.=3.4).
86. Geomela PA, **Kontos CK**, Yiotakis I, Scorilas A. Quantitative expression analysis of the apoptosis-related gene, *BCL2L12*, in head and neck squamous cell carcinoma. *J Oral Pathol Med.* 2013; 42(2): 154-61, (I.F.=2.7).
87. **Kontos CK** and Scorilas A. Molecular cloning of novel alternatively spliced variants of *BCL2L12*, a new member of the *BCL2* gene family, and their expression analysis in cancer cells. *Gene.* 2012; 505(1): 153-66, (I.F.=2.6).
88. Papageorgiou S*, **Kontos CK***, Pappa V, Thomadaki H, Kontsioti F, Dervenoulas J, Papageorgiou E, Economopoulos T, Scorilas A. The novel member of the *BCL2* gene family, *BCL2L12*, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker. *Oncologist.* 2011; 16(9): 1280-91, (I.F.=4.8).
*Equal Contributors.
89. Fendri A*, **Kontos CK***, Abdelmajid K, Mokdad-Gargouri R, Scorilas A. *BCL2L12* is a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma. *Mol Med.* 2011; 17(3-4): 163-71, (I.F.=6.0).
*Equal Contributors.
90. Fendri A, **Kontos CK**, Abdelmajid K, Mokdad-Gargouri R, Ardavanis A, Scorilas A. Quantitative analysis of *BCL2* mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor. *Tumor Biol.* 2010; 31(5):391-9.
91. **Kontos CK**, Papadopoulos IN, Fragoulis EG, Scorilas A. Quantitative expression analysis and prognostic significance of *L*-DOPA Decarboxylase (*DDC*) in colorectal adenocarcinoma. *Brit J Cancer.* 2010; 102(9): 1384-90, (I.F.=6.4).
92. Psyrri A, Papageorgiou S, Liakata E, Scorilas A, Rontogianni D, **Kontos CK**, Argyriou P, Pectasides D, Harhalakis N, Pappa V, Kolialexi A, Economopoulou C, Kontsioti F, Maratou E, Dimitriadis G, Economopoulou P, Economopoulos T. *Phosphatidylinositol 3'-kinase catalytic subunit α* gene amplification contributes to the pathogenesis of mantle cell lymphoma. *Clin Cancer Res.* 2009; 15(18): 5724-32, (I.F.=10.0).
93. **Kontos CK**, Papadopoulos IN, Scorilas A. Quantitative expression analysis and prognostic significance of the novel apoptosis-related gene *BCL2L12* in colon cancer. *Biol Chem.* 2008; 389(12): 1467-75, (I.F.=2.9).

Short Communications

94. Papatsirou M, Scorilas A, Sideris DC, **Kontos CK***. Targeted nanopore sequencing for the identification of novel *PRMT1* circRNAs unveils a diverse transcriptional profile of this gene in breast cancer cells. *Genes Dis.* 2023; 11(2):589-592, (I.F.=6.9).

*Corresponding Author.

Letters to the Editor

95. Papageorgiou SG, **Kontos CK**, Kotsianidis I, Karousi P, Symeonidis A, Galanopoulos G, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V. Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group. *J Geriatr Oncol.* 2020; 11(1): 121-4, (I.F.=3.0).
96. Karousi P, Katsaraki K, Papageorgiou SG, Pappa V, Scorilas A, **Kontos CK***. Identification of a novel tRNA-derived RNA fragment exhibiting high prognostic potential in chronic lymphocytic leukemia. *Hematol Oncol.* 2019; 37(4): 498-504, (I.F.=3.3).
- *Corresponding Author.
97. Papageorgiou SG, Kotsianidis I, **Kontos CK**, Symeonidis A, Galanopoulos A, Hatzimichael E, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V. Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study Group. *Leuk Res.* 2018; 71: 55-59, (I.F.=2.1).
98. Papageorgiou S, **Kontos CK**, Foukas PG, Panopoulou E, Vasilatou D, Rapti SM, Gkontopoulos K, Bazani E, Panayiotides IG, Dimitriadis G, Scorilas A, Pappa V. BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era. *Leuk Lymphoma.* 2016; 57(9): 2199-203, (I.F.=2.2).

Reviews

99. Aghiorghiesei AI, Mehterov N, Nutu A, Vladimirov B, Nonchev B, **Kontos CK**, Buduru R, Braicu C, Berindan-Neagoe I. The oncogenic role of miR-155 on oral cancer progression and treatment strategies. *Discov Oncol.* 2025; 16(1):1941 (I.F.=2.8).
100. Aghiorghiesei AI, Nutu A, Mehterov N, **Kontos CK**, Vladimirov B, Buduru R, Braicu C, Berindan-Neagoe I. Roles of miR-181 Family Members in OSCC: Implications for Therapy and Diagnostics. *Cancer Med.* 2025; 14(19):e71266 (I.F.=2.9).
101. Sotiropoulou CD, Festas K, **Kontos CK**, Makris MP, Foukas PG, Papageorgiou SG. Pathogenic Mechanisms of Systemic Mastocytosis: Unraveling the Genetic Complexity, Bone Marrow Microenvironment, and Clinical Challenges. *Eur J Haematol.* 2025; 115(4):308-321 (I.F.=2.3).
102. Rostom MM, Rashwan AA, Sotiropoulou CD, Hozayen SZ, Abdelhamid AM, Abdelhalim MM, Eltahtawy O, Emara HM, Elemam NM, **Kontos CK**, Youness RA. *MIAT*: A pivotal oncogenic long noncoding RNA tuning the hallmarks of solid malignancies. *Transl Oncol.* 2025; 54:102329 (I.F.=4.5).
103. Amr Elmasri R, Rashwan AA, Hany Gaber S, Mosaad Rostom M, Karousi P, Yasser MB, **Kontos CK**, Youness RA. Puzzling out the role of *MIAT* LncRNA in hepatocellular carcinoma. *Noncoding RNA Res.* 2024; 9(2):547-559 (I.F.=5.9).
104. Abaza T, El-Aziz MKA, Daniel KA, Karousi P, Papatsirou M, Fahmy SA, Hamdy NM, **Kontos CK***, Youness RA*. Emerging Role of Circular RNAs in Hepatocellular Carcinoma Immunotherapy. *Int J Mol Sci.* 2023; 24(22):16484, (I.F.=4.9).

*Corresponding Authors.

- 105.Eid M, Karousi P, Kunovský L, Tuček Š, Brančíková D, Kala Z, Slabý O, Mayer J, **Kontos CK***, Trna J*. The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma. *Biomedicines*. 2021; 9(10):1468, (I.F.=3.9).

*Corresponding Authors.

- 106.Papatsirou M, Artemaki PI, Karousi P, Scorilas A, **Kontos CK***. Circular RNAs: Emerging Regulators of the Major Signaling Pathways Involved in Cancer Progression. *Cancers*. 2021; 13(11):2744, (I.F.=4.5).

*Corresponding Author.

- 107.Artemaki PI, Letsos PA, Zoupa IC, Katsaraki K, Karousi P, Papageorgiou SG, Pappa V, Scorilas A, **Kontos CK***. The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas. *Biomedicines*. 2021; 9(4):333, (I.F.=3.9).

*Corresponding Author.

- 108.Papanota AM, Karousi P, **Kontos CK**, Ntanas-Stathopoulos I, Scorilas A, Terpos E. The Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background. *Int J Mol Sci*. 2021; 22(5):2375, (I.F.=4.9).

- 109.Katsaraki K, Karousi P, Artemaki PI, Scorilas A, Pappa V, **Kontos CK***, Papageorgiou SG*. MicroRNAs: tiny regulators of gene expression with pivotal roles in normal B-cell development and B-cell chronic lymphocytic leukemia. *Cancers*. 2021; 13(4):593, (I.F.=4.5).

*Corresponding Authors.

- 110.Papatsirou M, Artemaki PI, Scorilas A, **Kontos CK***. The role of circular RNAs in therapy resistance of patients with solid tumors. *Per Med*. 2020; 17(6):469-490, (I.F.=1.7).

*Corresponding Author.

- 111.Artemaki PI, Scorilas A, **Kontos CK***. Circular RNAs: A New Piece in the Colorectal Cancer Puzzle. *Cancers*. 2020; 12(9):2464, (I.F.=4.5).

*Corresponding Author.

- 112.Tsiakanikas P, Giaginis C, **Kontos CK**, Scorilas A. Clinical utility of MicroRNAs in renal cell carcinoma: Current evidence and future perspectives. *Expert Rev Mol Diagn*. 2018; 18(11): 981-91, (I.F.=3.9).

- 113.**Kontos CK**, Adamopoulos PG, Scorilas A. Prognostic and predictive biomarkers in prostate cancer. *Expert Rev Mol Diagn*. 2015; 15(12): 1567-76, (I.F.=3.9).

- 114.Christodoulou MI, **Kontos CK**, Halabalaki M, Skaltsounis AL, Scorilas A. Nature promises new anticancer agents: interplay with the apoptosis-related BCL2 family. *Anti-Cancer Agent Med*. 2014; 14(3): 375-99, (I.F.=2.6).

- 115.**Kontos CK***, Christodoulou MI, Scorilas A. Apoptosis-related BCL2-family members: key players in chemotherapy. *Anti-Cancer Agent Med*. 2014; 14(3): 353-74, (I.F.=2.6).

*Corresponding Author.

- 116.**Kontos CK**, Scorilas A, Papavassiliou AG. The role of transcription factors in laboratory medicine. *Clin Chem Lab Med*. 2013; 51(8): 1563-71, (I.F.=3.8).

- 117.**Kontos CK**, Mavridis K, Talieri M, Scorilas A. Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: Mechanistic and clinical aspects. *Thromb Haemost*. 2013; 110(3): 450-7, (I.F.=5.0).

- 118.**Kontos CK** and Scorilas A. Kallikrein-related peptidases (KLKs): A gene family of novel cancer biomarkers. *Clin Chem Lab Med*. 2012; 50(11): 1877-91, (I.F.=3.8).

Mini-Reviews

119. Katsaraki K, Scorilas A, **Kontos CK***. *SCAF1* (SR-related CTD-associated factor 1). *Atlas Genet Cytogenet Oncol Haematol*. 2021; 25(1): 52-56.
*Corresponding Author.
120. Karousi P, Scorilas A, **Kontos CK***. *KLK14* (kallikrein-related peptidase 14). *Atlas Genet Cytogenet Oncol Haematol*. 2021; 25(1): 44-50.
*Corresponding Author.
121. Karousi P, Scorilas A, **Kontos CK***. *KLK12* (kallikrein-related peptidase 12). *Atlas Genet Cytogenet Oncol Haematol*. 2020; 24(12): 451-6.
*Corresponding Author.
122. Artemaki PI, Pavlou MAS, **Kontos CK***. *BCL2L15* (BCL2-like 15). *Atlas Genet Cytogenet Oncol Haematol*. 2020; 24(12): 445-50.
*Corresponding Author.
123. Tsouraki D and **Kontos CK***. *CEACAM19* (carcinoembryonic antigen related cell adhesion molecule 19). *Atlas Genet Cytogenet Oncol Haematol*. 2020; 24(4): 152-5.
*Corresponding Author.
124. Karousi P, **Kontos CK**, Scorilas A. *KLK6* (kallikrein-related peptidase 6). *Atlas Genet Cytogenet Oncol Haematol*. 2020; 24(2): 79-82.
125. Artemaki PI, Scorilas A, **Kontos CK***. *BOK* (BCL2 family apoptosis regulator BOK). *Atlas Genet Cytogenet Oncol Haematol*. 2019; 23(10): 299-303.
*Corresponding Author.
126. **Kontos CK**, Pavlou MAS, Giaginis C. *MCM5* (minichromosome maintenance complex component 5). *Atlas Genet Cytogenet Oncol Haematol*. 2011; 15(12): 1045-9.
127. **Kontos C**, Thomadaki H, Scorilas A. *BCL2L12* (BCL2-like 12 (proline-rich)). *Atlas Genet Cytogenet Oncol Haematol*. 2009; 13(7): 467-8.

Commentaries

128. **Kontos CK***. Surrogate prognostic biomarkers in OSCC: the paradigm of PA28 γ overexpression. *EBioMedicine*. 2015; 2(8):784-5, (I.F.=9.7).
*Corresponding Author.

Editorials

129. Artemaki PI, **Kontos CK***. Alternative Splicing in Human Physiology and Disease. *Genes (Basel)*. 2022; 13(10):1820, (I.F.=2.8).
*Corresponding Author.
130. Artemaki PI, **Kontos CK***. Editorial for the Special Issue "Molecular Biomarkers in Colorectal Adenocarcinoma". *Int J Mol Sci*. 2021; 22(4):2052, (I.F.=4.9).
*Corresponding Author.

F2. Chapters in International, Peer-Reviewed Scientific Books

1. **Kontos CK***, Avgeris A, Scorilas A. Biomarkers with prognostic potential in prostate cancer. In: *Frontiers in Drug Design and Discovery*; 1st Ed., *Bentham Science Publishers*, edited by: Prof. Atta-ur-Rahman and M. Iqbal Choudhary, 2018.
**Corresponding Author.*
2. **Kontos CK**, Adamopoulos PG, Scorilas A. Molecular biomarkers of laryngeal cancer. In: *Biomarkers in Disease: Methods, Discoveries and Applications: Biomarkers in Cancer*, 1st Ed., *Springer*, edited by: Victor R. Preedy and Vinood B. Patel, 2014.
3. **Kontos CK**, Vasilatou D, Papageorgiou SG, Scorilas A. Translation regulation by microRNAs in acute leukemia. In: *Meyers: Encyclopedia of Molecular Cell Biology and Molecular Medicine: RNA Biology*, 2nd Ed., *Wiley*, edited by: Robert A. Meyers, 2013.

F3. Abstracts in Proceedings of International Conferences

1. Papatsirou M, **Kontos CK**, Ntanasis-Stathopoulos I, Liacos CI, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Scorilas A, Terpos E. Long-read nanopore sequencing uncovers the potential of circNFATC3 as a candidate prognostic biomarker in multiple myeloma. *Int Soc Enz Meeting*: 2026.
2. **Kontos CK**, Christodoulou S, Ivanova T, Kokoropoulos P, Kazakova M, Arkadopoulos N, Sarafian V. Uncovering the alternative post-transcriptional regulation of the human lysosomal associated membrane protein 1 (*LAMP1*) mRNAs in colorectal cancer. *Int Soc Enz Meeting*: 2026.
3. **Kontos CK**, Kokoropoulos P, Ivanova T, Christodoulou S, Mehterov N, Arkadopoulos N, Sarafian V. Discovery of alternatively spliced transcripts of the human gene encoding the lysosomal associated membrane protein 2 (*LAMP2*) in colorectal cancer. *Int Soc Enz Meeting*: 2026.
4. Sotiropoulou CD, Papageorgiou SG, **Kontos CK**, Bouchla A, Hatzilygeroudi T, Vryttia P, Apostolopoulou C, Markaki I, Karamanou G, Karantanos T, Pappa V. Deciphering the role of ATF4-PPP1R15A in acute myeloid leukemia chemoresistance. *Int Soc Enz Meeting*: 2026.
5. Sotiropoulou CD, **Kontos CK**, Papageorgiou SG, Scorilas A, Pappa V. Discovery of novel circRNAs in hematological malignancies by integration of nanopore sequencing and next-generation sequencing data. *Int Soc Enz Meeting*: 2026.
6. Sotiropoulou CD, Papageorgiou SG, Pappa V, Scorilas A, **Kontos CK**. Direct RNA sequencing based on nanopore technology uncovers known and novel long non-coding RNAs in leukemia and myelodysplastic syndrome. *Proc FEBS*: 2026.
7. Papatsirou M, **Kontos CK**, Ntanasis-Stathopoulos I, Liacos CI, Tsiakanikas P, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Moreaux J, Scorilas A, Terpos E. A novel circular RNA produced by the “Nuclear factor of activated T-cells, cytoplasmic 3” gene (circNFATC3), discovered by nanopore sequencing, holds significant prognostic value in multiple myeloma. *Proc EHA*: 2026.
8. Athanasopoulou K, Adamopoulos PG, Ntanasis-Stathopoulos I, **Kontos CK**, Terpos E. Comparative transcriptomic profiling of IgG and IgA-producing human multiple myeloma cell lines reveals isotype-specific gene expression signatures. *Proc EHA*: 2026.
9. **Kontos CK**, Kalogerini K, Athanasopoulou K, Ntanasis-Stathopoulos I, Scorilas A, Trougakos IP, Terpos E. Novel alternative splice variants of genes encoding lysosome-associated membrane proteins 1 and 2 (*LAMP1* and *LAMP2*) in multiple myeloma, revealed by combining next-generation and nanopore sequencing. *Proc EHA*: 2026.

10. Sotiropoulou CD, **Kontos CK**, Bouchla A, Hatzilygeroudi T, Papageorgiou SG, Vryttia P, Apostolopoulou C, Markaki I, Karamanou G, Karantanos T, Pappa V. Unravelling the mechanism of chemoresistance in AML: the role of *ATF4-PPP1R15A* axis. *Proc EHA*: 2026.
11. Sotiropoulou CD, Papageorgiou SG, Pappa V, Scorilas A, **Kontos CK**. Direct RNA sequencing based on nanopore technology uncovers known and novel long non-coding RNAs in leukemia and myelodysplastic syndrome. *Proc FEBS*: 2026.
12. Athanasopoulou K, Adamopoulos PG, Ntanasis-Stathopoulos I, Moreaux J, Scorilas A, Terpos E, **Kontos C**. Long non-coding RNA (lncRNA) expression signatures distinguish drug response phenotypes in multiple myeloma cell line models. *Proc ASH*: 2025.
13. Papatsirou M, **Kontos C**, Ntanasis-Stathopoulos I, Tsiakanikas P, Liacos CI, Gavriatopoulou M, Kastritis E, Dimopoulos M, Moreaux J, Scorilas A, Terpos E. Nanopore sequencing-based profiling of circular RNAs in multiple myeloma uncovers circNFATC3 as a promising prognostic biomarker. *Proc ASH*: 2025.
14. Sotiropoulou C, **Kontos C**, Bouchla A, Chatziligeroudi T, Papageorgiou S, Vitsioti A, Apostolopoulou C, Markaki I, Karamanou G, Karantanos T, Pappa V. PPP1R15A as a therapeutic target to overcome chemoresistance in AML: An in vitro study. *Proc ASH*: 2025.
15. **Kontos CK**. Circular RNAs: highly promising molecular biomarkers in hematological malignancies. *Int Soc Enz Meeting*: 2025.
16. Katsaraki K, Vatsellas G, Sideris DC, Scorilas A, **Kontos CK**. Circular RNAs originating from the *BAX* gene unveil new layers of post-transcriptional regulation in breast cancer. *Int Soc Enz Meeting*: 2025.
17. Sotiropoulou CD, Bouchla, Esteb C, Loupis T, Papageorgiou SG, Delikonstantinos GG, Pagoni M, Hatzimichael E, Delatola M, Kalomoiri S, Apostolidou E, **Kontos CK**, Thomopoulos TP, Karantanos T, Pappa V. Suppressing *PPP1R15A* sensitizes acute myeloid leukemia cells to chemotherapeutic agents by disrupting DNA repair mechanisms. *Int Soc Enz Meeting*: 2025.
18. Youness R., Ahmed N., Dawoud A., Youssef Y., Abdelaal A., Attia A., Metwally A., Coulouarn C., **Kontos C**. Hsa_circ_0000284 (circHIPK3) and Hsa_circ_0001944 (circBCBM) are Novel Biomarkers for Early Detection of HCV-Induced Hepatocellular Carcinoma. *Proc ESMO GI*: 2025.
19. Sotiropoulou CD, Scorilas A, Pappa V, Papageorgiou SG, **Kontos CK**. Identification of Apoptosis-Related Circular RNAs in Hematological Malignancies by Coupling Nanopore Sequencing with Next-Generation Sequencing. *Proc FEBS*: 2025.
20. Papatsirou M, Terpos E, Moreaux J, Scorilas A, **Kontos CK**. Alternative splicing complexity results in a very diverse repertoire of circular RNAs in multiple myeloma, as revealed by nanopore sequencing. *Proc FEBS*: 2025.
21. Papatsirou M, **Kontos CK**, Ntanasis-Stathopoulos I, Sotiropoulou CD, Liacos CI, Gavriatopoulou M, Avgeris M, Kastritis E, Dimopoulos MA, Moreaux J, Scorilas A, Terpos E. Circular RNA Profiling Using High-Accuracy Long-Read Nanopore Sequencing of Multiple Myeloma Cell Lines Reveals the Wide Diversity of the Circular Transcriptome. *Proc ASH*: 2024.
22. Papatsirou M, Scorilas A, **Kontos CK**. Expression analysis of circular RNAs (circRNAs) in multiple myeloma cell lines, using a novel experimental approach based on nanopore sequencing. *Int Soc Enz Meeting*: 2024.
23. Diamantopoulos MA, Georgoulia KK, Levis P, Kotronopoulos G, Stravodimos K, **Kontos CK**, Avgeris M, Scorilas A. 28S rRNA-Derived Fragments Represent an Independent Molecular Predictor of Short-Term Relapse in Prostate Cancer. *Int Soc Enz Meeting*: 2024.

24. Papatsirou M, Scorilas A, Kletsas D, **Kontos CK**. Utilizing a cutting-edge nanopore sequencing strategy to uncover novel circRNAs from the human *PRMT1* gene in breast cancer cell lines. *Int Soc Enz Meeting*: 2024.
25. Sotiropoulou CD, **Kontos CK**, Avgeris M, Hatzinikolaou DG, Scorilas A. Harnessing the microbial biodiversity of Greece: Development of indigenous starter cultures for yogurt production. *Int Soc Enz Meeting*: 2024.
26. Katsaraki K, Sideris DC, Scorilas A, **Kontos CK**. Shedding light on breast cancer cell signaling: promising epigenetic regulation of signaling genes by microRNAs. *Proc FEBS*: 2024.
27. Karousi P, Scorilas A, Sideris DC, Carell T, **Kontos CK**. circ-BCL2L12-92, a novel circular RNA derived from *BCL2L12*, is able to regulate the mRNA levels of its parental gene. *Proc FEBS*: 2024.
28. Papatsirou M, Machairas NP, Karousi P, Ntanasis-Stathopoulos I, Dimitriadou A, Xenou K, Fotiou D, Liacos CI, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Scorilas A, Terpos E, **Kontos CK**. Identification and quantification of novel circular RNAs (circRNAs) deriving from the apoptosis-related *BCL2L12* gene in multiple myeloma cells, using targeted nanopore sequencing and nested qPCR. *Proc IMS*: 2023.
29. Papatsirou M, Ntanasis-Stathopoulos I, Karousi P, Malandrakis P, Fotiou D, Liacos CI, Gavriatopoulou M, Kastritis E, Scorilas A, Dimopoulos MA, **Kontos CK**, Terpos E. Biomarker utility of circRNAs in multiple myeloma: The exemplary cases of ciRS-7 and *circCCT3* as surrogate prognostic molecular biomarkers combined with the R-ISS staging system. *Proc IMS*: 2023.
30. Dimitriadou A, Karousi P, Abdelgawad A, Sotiropoulou CD, Artemaki PI, Papageorgiou SG, Scorilas A, Batish M, **Kontos CK**. Nanopore sequencing unveils novel circular transcripts of apoptosis-related genes in human leukemic cells. *Int Soc Enz Meeting*: 2023.
31. Karousi P, Gianniou DD, Sarikaki G, **Kontos CK**, Kostakis IK, Skaltsounis AL, Trougakos IP, Scorilas A. Exploring the differential effects of GS32 compound from *Olea europaea* on gene expression and pathway modulation in tumor vs. normal human cells. *Int Soc Enz Meeting*: 2023.
32. Karousi P, Angelis N, **Kontos CK**, Kostakis IK, Skaltsounis AL, Tsitsilonis OE, Scorilas A. Investigating the expression profile of inflammation-related microRNAs in THP-1 cells treated with lipopolysaccharide and *Olea europaea* compounds. *Int Soc Enz Meeting*: 2023.
33. Katsaraki K, **Kontos CK**, Ardavanis G, Tzovaras AA, Sideris DC, Scorilas A. Paving the way to the recognition of the miRNA regulatory potential in breast cancer, upon proteasome inhibition: a comprehensive analysis of miRNA expression profiles. *Int Soc Enz Meeting*: 2023.
34. Papatsirou M, Kletsas D, Scorilas A, **Kontos CK**. Application of an innovative nanopore sequencing-based approach to identify novel circRNAs of the human PRMT1 gene in a panel of breast cancer cell lines. *Proc FEBS*: 2023.
35. Papatsirou M, **Kontos CK**, Ntanasis-Stathopoulos I, Malandrakis P, Theodorakakou F, Liacos CI, Mavrianou-Koutsoukou N, Fotiou D, Migkou M, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Scorilas A, Terpos E. The circular RNA of the chaperonin-containing TCP1 subunit 3 gene (circ-CCT3) is overexpressed in multiple myeloma and predicts a favorable prognostic outcome, independently of the R-ISS staging. *Proc EHA*: 2023.
36. Karousi P, **Kontos CK**, Kostakis IK, Skaltsounis AL, Avgeris M, Scorilas A. Next-generation sequencing reveals altered gene expression and enriched pathways in triple-negative breast cancer cells treated with oleuropein and oleocanthal. *Proc Can Front*: 2023.
37. Papatsirou M, **Kontos CK**, Ntanasis-Stathopoulos I, Karousi P, Malandrakis P, Theodorakakou F, Liacos CI, Liosi AA, Kalioraki MA, Mavrianou-Koutsoukou N, Fotiou D, Migkou M, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Scorilas A, Terpos E. The Cancer-Related

circRNA ciRS-7 (CDR1-AS) Is Differentially Expressed in CD138+ Cells of Patients With Plasma Cell Disorders and Predicts Unfavorable Overall Survival in Multiple Myeloma. *Proc ASH*: 2022.

38. **Kontos CK**. The emerging roles of circular RNA (circRNA) molecules: key regulators of gene expression dictating human disease development and progression. *Int Soc Enz Meeting*: 2022.
39. Karousi P, **Kontos CK**, Scorilas A. Development of two Perl-based algorithms for the sensitive analysis of long-read, targeted circRNA sequencing data, obtained using nanopore sequencing. *Int Soc Enz Meeting*: 2022.
40. **Kontos CK**, Karousi P, Scorilas A. Development of a sensitive, quantitative PCR-based assay for apoptosis-related genes and its application in human cancer cells treated with extracts deriving from *Olea europaea*. *Int Soc Enz Meeting*: 2022.
41. Karousi P, Kostakis IK, **Kontos CK**, Skaltsounis AL, Scorilas A. Apoptosis-related miRNAs show different expression levels between ovarian cancer cells treated with natural products from *Olea europaea*. *Int Soc Enz Meeting*: 2022.
42. Papatsirou M, Katsaraki K, Diamantopoulos MA, Scorilas A, **Kontos CK**. Novel circular RNAs of the human *PRMT1* gene emerge from a wide variety of splicing events in breast cancer. *Int Soc Enz Meeting*: 2022.
43. Sotiropoulou CD, Kostopoulou I, Talagani S, Magou E, Nikolaou M, Ardavanis A, **Kontos CK**, Scorilas A. Treatment of prostate cancer cells with proteasome inhibitors alters the mRNA expression levels of apoptosis-related genes. *Int Soc Enz Meeting*: 2022.
44. Katsaraki K, Ardavanis G, Perdikari K, Drizou M, Maragos C, Dokou A, **Kontos CK**, Scorilas A. Unraveling the diverse sensitivity of breast cancer cells of distinct molecular subtypes to proteasome inhibitors. *Int Soc Enz Meeting*: 2022.
45. Hadjichambi D, Karousi P, Artemaki PI, Scorilas A, **Kontos CK**. Discovery of novel circular RNAs (circRNAs) of the *BOK* gene in human prostate and ovarian cancer cell lines, using nanopore sequencing. *Int Soc Enz Meeting*: 2022.
46. Machairas N, Karousi P, Scorilas A, **Kontos CK**. Discovery of novel circular RNAs of the apoptosis-related *BCL2L12* gene in multiple myeloma cells, using targeted 3rd generation (nanopore) sequencing. *Int Soc Enz Meeting*: 2022.
47. Artemaki PI, Scorilas A, Batish M, **Kontos CK**. Novel transcripts of human apoptosis-related *BCL2-ovarian killer (BOK)* question our knowledge about this gene and its products in human cancer cells. *Proc FEBS*: 2022.
48. Artemaki PI, Karousi P, Papageorgiou S, Pappa V, Scorilas A, **Kontos CK**. 3rd-generation (nanopore) sequencing unveils novel circular RNAs (circRNAs) of the human apoptosis-related *BAX* gene in leukemic cells, providing evidence for an alternative back-splicing mechanism. *Proc FEBS*: 2022.
49. Karousi P, Scorilas A, Sideris DC, **Kontos CK**. Novel circular RNAs (circRNAs) of the human apoptosis-related *BCL2L12* gene, discovered using targeted 3rd generation (nanopore-based) sequencing, disclose novel aspects of circRNA biology. *Proc FEBS*: 2022.
50. Artemaki P, Machairas N, Karousi P, Pappa V, Scorilas A, Papageorgiou S, Batish M, **Kontos C**. Discovery of novel circular RNAs (circRNAs) of the apoptosis-related *BAX* and *BCL2L12* genes with a multifaceted role in chronic lymphocytic leukemia, using cutting-edge nanopore sequencing technology. *Proc EHA*: 2022.
51. Xenou K, Sotiropoulou C, Karousi P, Machairas N, Scorilas A, Pappa V, Papageorgiou S, **Kontos C**. Targeted 3rd-generation (nanopore) sequencing reveals many novel circular RNAs of the apoptosis-related *BCL2L12* gene, expressed in human cells from acute myeloid leukemia and myelodysplastic syndromes. *Proc EHA*: 2022.

52. Artemaki PI, Adamopoulos PG, Scorilas A, **Kontos CK**. Transcriptional analysis of *BAX*-like members of *BCL2* family in colorectal cancer cell lines, using targeted 3rd generation sequencing. *Int Soc Enz Meeting*: 2021.
53. Karousi P, Scorilas A, **Kontos CK**. *BCL2L12* circRNAs: new pieces in the complex transcriptome puzzle, discovered using nanopore sequencing technology. *Int Soc Enz Meeting*: 2021.
54. Katsaraki K, Scorilas A, **Kontos CK**. Targeted 3rd-generation sequencing reveals novel circular transcripts of the human *BAX* gene. *Int Soc Enz Meeting*: 2021.
55. Papatsirou M, **Kontos CK**, Scorilas A. Long-read sequencing reveals a wide variety of novel circular RNAs deriving from the human *PRMT1* gene. *Int Soc Enz Meeting*: 2021.
56. Sotiropoulou CD, Katsaraki K, **Kontos CK**, Scorilas A. Treatment of prostate cancer cells with bortezomib and carfilzomib triggers alteration in the mRNA expression levels of *BCL2* family members. *Int Soc Enz Meeting*: 2021.
57. Katsaraki K, Ardavanis G, Drizou M, Giasmin EX, Perdikari K, **Kontos CK**, Scorilas A. Breast cancer cells with different genetic background show diverse sensitivity to proteasome inhibitors. *Int Soc Enz Meeting*: 2021.
58. Karousi P, **Kontos CK**, Scorilas A. Development of a sensitive, quantitative PCR-based assay for apoptosis-related miRNAs and its application in human cancer cells treated with extracts deriving from *Olea Europea*. *Int Soc Enz Meeting*: 2021.
59. Karousi P, Artemaki PI, Sotiropoulou CD, Papatsirou M, Katsaraki K, Scorilas A, **Kontos CK**. Identification of five novel circular RNAs deriving from *BCL2L12* apoptosis-related gene in colon cancer cell lines. *Proc FEBS*: 2021.
60. Artemaki PI, Tsouraki DG, Scorilas A, **Kontos CK**. Transcriptional analysis of the human apoptosis-related *BOK* gene reveals novel, alternatively spliced messenger RNAs, a previously unknown 5' untranslated region (5' UTR), and two new, shorter 3' UTRs. *Proc FEBS*: 2021.
61. Papanota AM, Tsiakanikas PI, **Kontos CK**, Malandrakis P, Liacos C, Ntanas-Stathopoulos I, Kanellias N, Gavriatopoulou M, Kastritis E, Avgeris M, Dimopoulos MA, Scorilas A, Terpos E. The clinical utility of a plasma miRNA signature in multiple myeloma bone disease. *Proc EHA*: 2021.
62. Karousi P, Papanota AM, **Kontos CK**, Liacos C, Artemaki PI, Patseas D, Liosi AA, Mavrianou-Koutsoukou N, Kalioraki MA, Fotiou D, Ntanas-Stathopoulos I, Migkou M, Malandrakis P, Gavriatopoulou M, Kastritis E, Scorilas A, Dimopoulos MA, Terpos E. tRNA-derived RNA fragments in plasma cells: promising molecular biomarkers of prognosis in multiple myeloma. *Proc EMN*: 2021.
63. Papanota AM, Karousi P, **Kontos CK**, Liacos C, Artemaki PI, Patseas D, Papadimitriou M, Eleutherakis-Papaiakovou E, Avgeris M, Kanellias N, Bagratuni T, Roussou M, Dialoupi I, Kastritis E, Gavriatopoulou M, Scorilas A, Dimopoulos MA, Terpos E. A cancer-related microRNA signature predicts osteolytic disease and exhibits prognostic potential in multiple myeloma. *Proc EMN*: 2021.
64. Karousi P, Katsaraki K, Papageorgiou SG, Pappa V, Sideris DC, Scorilas A, **Kontos CK**. Two novel tRNA-derived RNA fragments possess clinical utility as molecular biomarkers in chronic lymphocytic leukemia. *1st Transl Conf: CLL*: 2020.
65. Papanota A, Artemaki P, Karousi P, Liacos C, Gavriatopoulou M, Kastritis E, **Kontos C**, Dimopoulos M, Scorilas A, Terpos E. A novel microRNA signature with clinical significance in multiple myeloma. *Proc EHOC*: 2020.
66. Artemaki PI, Papanota AM, Karousi P, Liacos C, **Kontos CK**, Patseas D, Papadimitriou MA, Eleutherakis-Papaiakovou E, Avgeris M, Kanellias N, Bagratuni T, Roussou M, Dialoupi I,

- Kastritis E, Gavriatopoulou M, Dimopoulos MA, Scorilas A, Terpos E. The clinical significance of a novel microRNA signature in multiple myeloma. *Proc ASH*: 2019.
67. Karousi P, Papanota AM, Artemaki PI, Liacos C, **Kontos CK**, Patseas D, Liosi AA, Mavrianou-Koutsoukou N, Kalioraki MA, Fotiou D, Ntanasis-Stathopoulos I, Migkou M, Malandrakis P, Gavriatopoulou M, Kastritis E, Terpos E, Scorilas A, Dimopoulos MA. A molecular signature of three tRNA-derived RNA fragments may discriminate smoldering from symptomatic multiple myeloma patients. *Proc ASH*: 2019.
 68. Papanota AM, Karousi P, **Kontos CK**, Liacos C, Artemaki PI, Patseas D, Liosi AA, Mavrianou-Koutsoukou N, Kalioraki MA, Fotiou D, Ntanasis-Stathopoulos I, Migkou M, Malandrakis P, Kastritis E, Gavriatopoulou M, Scorilas A, Dimopoulos MA, Terpos E. Three tRNA-Derived RNA Fragments (3'-tRF-LeuAAG/TAG, i-tRF-GluCTC, and i-tRF-ProTGG). Discriminate Smoldering from Symptomatic Multiple Myeloma Patients. *Proc AHOS*: 2019.
 69. Papanota AM, Artemaki PI, Karousi P, Liacos C, **Kontos CK**, Patseas D, Papadimitriou MA, Eleutherakis-Papaiakovou E, Avgeris M, Kanellias N, Bagratuni T, Roussou M, Dialoupi I, Kastritis E, Gavriatopoulou M, Scorilas A, Dimopoulos MA, Terpos E. The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma. *Proc AHOS*: 2019.
 70. Tsiakanikas P, Morrou M, Karousi P, Adamopoulos PG, Panoutsopoulou K, **Kontos CK**, Scorilas A. Identification and study of alternative 3'-untranslated regions (3'-UTRs) of kallikrein-related peptidase (KLK) gene family members using next-generation sequencing (NGS). *Proc Int Symp Kallikr*: 2019.
 71. Artemaki PI, Scorilas A, **Kontos CK**. Identification of new transcripts of the human *BOK* gene, a *BCL2* family member. *Int Soc Enz Meeting*: 2019.
 72. Karagiorgou S, Artemaki PI, **Kontos CK**, Scorilas A. Treatment of human colon cancer cells with natural and classical anticancer drugs triggers apoptosis, involving *BCL2* family members, including *BCL2L12* and *BOK*. *Int Soc Enz Meeting*: 2019.
 73. Karousi P, Katsaraki K, Adamopoulos PG, Papageorgiou SG, Pappa V, Scorilas A, **Kontos CK**. Identification of two novel tRNA-derived RNA fragments exhibiting high prognostic potential in chronic lymphocytic leukemia. *Int Soc Enz Meeting*: 2019.
 74. Papatsirou M, Adamopoulos PG, Scorilas A, Vassilacopoulou D, **Kontos CK**. Detection of novel, alternatively spliced transcripts of the human *L-DOPA* decarboxylase (*DDC*) gene in cancer cells by next-generation sequencing. *Int Soc Enz Meeting*: 2019.
 75. Papageorgiou SG, Katsaraki K, Karousi P, Tsiakanikas P, Scorilas A, Pappa V, **Kontos CK**. Identification of two novel tRNA-derived RNA fragments exhibiting high prognostic potential in chronic lymphocytic leukemia. *Proc ICML*: 2019.
 76. Galanopoulos A, Kamouza E, **Kontos CK**, *et al*. Prognostic significance of severe thrombocytopenia in overall survival of patients with myelodysplastic syndromes treated with azacytidine: a multicenter study by the Hellenic MDS Study Group. *Proc ASH*: 2018.
 77. Artemaki PI, Tsilikas N, Rapti SM, Adamopoulos PG, Scorilas A, **Kontos CK**. Alternative splicing of the *BCL2* family members produces new apoptosis-related protein isoforms with distinct combinations of *BCL2*-homology (BH) motifs. *Proc Adv Cancer Immunol Immunoth*: 2018.
 78. Boti MA, Papatsirou M, Tsiakanikas P, Adamopoulos PG, Scorilas A, Vassilacopoulou D, **Kontos CK**. Identification of new alternative splicing events resulting in novel splice variants of the human *L-DOPA* decarboxylase (*DDC*) gene in cancer cells, using next-generation sequencing technology. *Proc Adv Cancer Immunol Immunoth*: 2018.

79. Karousi P, Kamouza E, Diamantopoulos MA, Tsiakanikas P, **Kontos CK**, Papageorgiou SG, Scorilas A, Pappa V. A novel tRNA fragment as a molecular biomarker of poor prognosis in B-cell chronic lymphocytic leukemia. *Proc Adv Cancer Immunol Immunoth*: 2018.
80. Katsaraki K, Karagiorgou S, Tsiakanikas P, Adamopoulos PG, Papageorgiou SG, Pappa V, **Kontos CK**. tRNA-derived RNA fragments (tRFs) constitute a novel class of molecular biomarkers in B-cell chronic lymphocytic leukemia: the paradigm of a novel tRF predicting patients' overall survival. *Proc Adv Cancer Immunol Immunoth*: 2018.
81. Liosi AA, Kalioraki MA, Sklirou AD, Cheimonidi MC, **Kontos CK**, Scorilas A, Trougakis IP. Overexpression of the molecular chaperone Clusterin (*CLU*) and heat-shock protein beta-3 (*HSPB3*) mRNAs predicts colorectal cancer patients' relapse. *Proc Adv Cancer Immunol Immunoth*: 2018.
82. Morrou M, Karousi P, Adamopoulos PG, Tsiakanikas P, Scorilas A, **Kontos CK**. Alternative 3'-untranslated regions (3'-UTRs) in messenger RNAs of kallikrein-related peptidase (*KLK*) family members result from alternative splicing of *KLK* pre-mRNAs, as revealed by next-generation sequencing. *Proc Adv Cancer Immunol Immunoth*: 2018.
83. Tsiakanikas P, **Kontos CK**, Avgeris M, Diamantopoulos MA, Scorilas A. MicroRNA-15a, a novel molecular biomarker in colorectal cancer, predicting patients' relapse. *Proc Adv Cancer Immunol Immunoth*: 2018.
84. Adamopoulos PG, **Kontos CK**, Scorilas A. Identification of new transcripts of the human *KLK1* and *KLK2* genes. *Int Soc Enz Meeting*: 2018.
85. Diamantopoulos MA, **Kontos CK**, Papageorgiou SG, Pappa V, Scorilas A. MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia. *Int Soc Enz Meeting*: 2018.
86. **Kontos CK**, Adamopoulos PG, Scorilas A. Molecular cloning of novel alternative splice variants of the human tissue kallikrein (*KLK1*) and kallikrein-related peptidases 2, 5 – 12 (*KLK2*, *KLK5* – *KLK12*), using Next-Generation Sequencing (NGS) technology. *Int Soc Enz Meeting*: 2018.
87. Mavrogiannis A., Adamopoulos PG, **Kontos CK**, Scorilas A. Molecular cloning of novel alternative splice variants of the human protein arginine methyltransferase 1 (*PRMT1*) gene with the use of Next-Generation Sequencing. *Int Soc Enz Meeting*: 2018.
88. Pantiora KV, Georgousaki A, **Kontos CK**, Fokialakis N, Scorilas A. Isolation and biological study of secondary metabolites of microbial origin for the development of human anticancer agents. *Int Soc Enz Meeting*: 2018.
89. Tsiakanikas P, **Kontos CK**, Papageorgiou SG, Pappa V, Scorilas A. Elevated miR-20b-5p expression levels in peripheral blood mononuclear cells predict favorable prognosis in chronic lymphocytic leukemia. *Int Soc Enz Meeting*: 2018.
90. Zisi Z, Adamopoulos PG, **Kontos CK**, Scorilas A. Discovery of novel splice variants of the human carcinoembryonic antigen-related cell adhesion molecule 19 gene (*CEACAM19*), using Next-Generation Sequencing. *Int Soc Enz Meeting*: 2018.
91. Papageorgiou S, **Kontos CK**, Tsiambalis T, Vyniou A, Symeonidis A, Galanopoulos A, Kotsianidis I, Pappa V. The prognostic value of monosomal karyotype (MK) in high-risk patients with myelodysplastic syndromes treated with 5-azacitidine. *Proc ASH*: 2017.
92. Papageorgiou S, **Kontos CK**, Tsiambalis T, Vyniou A, Symeonidis A, Galanopoulos A, Kotsianidis I, Pappa V. The outcome of patients with high risk MDS achieving stable disease after treatment with 5-azacitidine. A retrospective analysis of the Hellenic (Greek) MDS Study Group. *Proc ASH*: 2017.

93. Galanopoulos AG, **Kontos CK**, Symeonidis A, *et al.* Prognosis of lower risk patients with myelodysplastic syndromes without isolated del(5q) after failure of erythropoiesis-stimulating agents. A multicenter study by the Hellenic MDS Study Group. *Proc ASH*: 2017.
94. Theofilatos K, Grafanaki K, **Kontos C**, Korfiati A, Mavroudi S, Anastasakis D, Skeparnias I, Kyriakopoulos G, Papaioannou D, Skordilas A, Drainas D, Stathopoulos C. Dissecting the effect of a novel synthetic retinoid-polyamine conjugate on mRNA and miRNA expression profiles of HaCaT cells. *Innov Can Prev Res Con*: 2017.
95. Adamopoulos PG, **Kontos CK**, Scorilas A. Molecular cloning of novel transcripts of human kallikrein-related peptidases 5, 6, 7, 8 and 9 (*KLK5 – KLK9*), using Next-generation sequencing. *Proc Int Symp Kallikr*: 2017.
96. Adamopoulos PG, **Kontos CK**, Scorilas A. Molecular cloning of novel alternatively spliced transcripts of human kallikrein-related peptidase 10 (*KLK10*) using next-generation sequencing. *Int Soc Enz Meeting*: 2017.
97. Raptis G, Adamopoulos P, **Kontos C**, Scorilas A. Discovery of novel transcripts of the *SCAF1* gene in human cancer cells, using next-generation sequencing technology. *Int Soc Enz Meeting*: 2017.
98. Tsiakanikas P, **Kontos CK**, Diamantopoulos MA, Christodoulou S, Papadopoulos IN, Scorilas A. Elevated tissue levels of miRNA-28-5p predict short-term relapse and poor overall survival of patients with colorectal adenocarcinoma. *Int Soc Enz Meeting*: 2017.
99. Adamopoulos PG, **Kontos CK**, Raptis GD, Scorilas A. Discovery of novel transcripts of the kallikrein-related peptidase (KLK) family with potential clinical utility as cancer biomarkers, using next-generation sequencing. *EuroMedLab*: 2017.
100. **Kontos CK**, Rapti SM, Tsiakanikas P, Papadopoulos IN, Scorilas A. MicroRNA-24-3p overexpression predicts relapse and poor overall survival of colorectal adenocarcinoma patients, independently of other established prognosticators. *EuroMedLab*: 2017.
101. **Kontos CK**, Kerimis D, Diamantopoulos MA, Papadopoulos IN, Scorilas A. High tissue levels of miR-15a-5p: a novel potential biomarker of recurrence in colorectal adenocarcinoma. *EuroMedLab*: 2017.
102. Grafanaki K, **Kontos C**, Korfiati A, Shaukat A, Papaioannou D, Scorilas A, Stathopoulos C, Drainas D. The synthetic retinoid-polyamine conjugate RASP induces S/G2 cell cycle arrest and DNA damage response on HaCat cells. *Proc EADO*: 2017.
103. Galanopoulos A, **Kontos CK**, Viniou NA, *et al.* Validation of the Revised International Prognostic Scoring System in 2582 patients with myelodysplastic syndrome. A multicenter study by the Hellenic MDS Study Group. *Proc ASH*: 2016.
104. Lappa IA, Tsigara EG, Tsigara MG, Kakaridi M, Scorilas A, Karantonis HC, **Kontos CK**. Extracts from Limnio red-wine grape skin trigger apoptosis in ovarian malignant adenocarcinoma cells through activation of the intrinsic apoptotic pathway. *Proc FEBS*: 2016.
105. Christodoulou MI, Avgeris M, Kokkinopoulou IK, Maratou E, Mitrou P, **Kontos CK**, Pappas E, Boutati E, Scorilas A, Raptis SA, Fragoulis EG. Investigation of the peripheral blood gene-expression signature in patients with type-2 diabetes mellitus, using mRNA next-generation sequencing. *Proc FEBS*: 2016.
106. **Kontos CK** and Scorilas A. Identification and characterization of novel cancer-related transcripts using next-generation sequencing (NGS). *Int Soc Enz Meeting*: 2016.
107. Adamopoulos PG, **Kontos CK**, Scorilas A. Identification of novel alternative splice variants of the Kallikrein genes in human cancer cells using next-generation sequencing analysis. *Int Soc Enz Meeting*: 2016.

108. Lappa IA, Michailidou KA, Apostolopoulou XK, Lagoumtzis TN, Avgeris M, Giaouris E, **Kontos CK**. Highly specific and sensitive PCR-based detection of *Escherichia coli* O157:H7 (O157), *Listeria monocytogenes* and *Salmonella* spp. in widely consumed foods. *Int Soc Enz Meeting*: 2016.
109. Diamantopoulos IM, Adamopoulos P, **Kontos CK**, Scorilas A. Molecular cloning of novel alternative transcripts of adaptor related protein complex 2 alpha 1 subunit (*AP2A1*) in human cancer cells, using next-generation sequencing. *Int Soc Enz Meeting*: 2016.
110. Klettas D, **Kontos CK**, Toutouzas K, Ageli C, Katsargyris A, Klonaris C, Scorilas A. Expression analysis of *KLK4*, *KLK9* and *KLK10* in human carotid atherosclerotic lesions. *Int Soc Enz Meeting*: 2016.
111. **Kontos CK**, Kladi-Skandali A, Tzovaras A, Theochari M, Kaltsas S, Gkeka D, Altanis C, Dokou A, Stamatopoulou S, Ardavanis A, Scorilas A. Study of alterations in the expression of cancer related-genes in tumor cells, in response to their treatment with chemotherapeutic drugs. *Int Soc Enz Meeting*: 2016.
112. Bakou V, Ioannidou ED, Vikentiou M, Konsta E, Spathis A, Kontsioti F, **Kontos C**, *et al*. Quantitative and qualitative analysis of regulatory T cells (Tregs) in B cell chronic lymphocytic leukemia (B-CLL). *Proc ASH*: 2015.
113. Kladi-Skandali A, Mavridis K, **Kontos CK**, Sideris DC, Scorilas A. Investigation of the effect of chemotherapeutic drugs on the multiple expression levels of the *KLKs*, *DDC*, *RNASEK* and *BCL2L12* genes in human breast and prostate cancer cells. New promising indicators for predicting chemotherapy response. *Proc Cancer Ther*: 2015.
114. Tsiakanikas P, **Kontos CK**, Adamopoulos P, Scorilas A. Molecular cloning of new *BCL2L12* transcript variants resulting from alternative splicing, using next-generation sequencing (NGS). *Int Soc Enz Meeting*: 2015.
115. Ioannidou ED, Bakou V, Vikentiou M, Konsta E, Kontsioti F, **Kontos C**, Vasilatou D, Mpouchla A, Gontopoulos K, Roubakis C, Stavroulaki G, Papanikolaou N, Atta M, Mpazani E, Papageorgiou S, Kokkori S, Kyriakou E, Dimitriadis G, Pappa V. Quantitative and qualitative analysis of regulatory T cells (Tregs) in B cell chronic lymphocytic leukemia (B-CLL). *Proc EHA*: 2015.
116. Gardikas N, Vikentiou M, Konsta E, Kapsimali V, **Kontos C**, Ioannidou E, Oikonomopoulou C, Bouhla A, Roubakis C, Papanikolaou N, Vasilatou D, Papageorgiou S, Dimitriadis G, Pappa V. Flow cytometric analysis of maturation-associated stages of CD34+ populations in the bone marrow of MDS patients. *Proc Int Symp MDS*: 2015.
117. Skourti E, Logotheti S, **Kontos CK**, Scorilas A, Trougakovs IP, Michalopoulos I, Zoumpourlis V. MiR-200 family miRNAs and miR-205 exhibit a functional role in the progression of the mouse skin carcinogenesis through downregulating specific oncogenes. *Proc Int Symp Mol Med*: 2014.
118. Anastasakis D, Grafanaki K, **Kontos C**, Skeparnias I, Apostolodi M, Konstantinidou P, Alexopoulos P, Gioutlakis A, Dougenis D, Drainas D, Moschonas NK, Scorilas A, Stathopoulos C. Monitoring the expression dynamics of networks controlling tRNA expression, signaling and translation in lung cancer. *tRNA Conf*: 2014.
119. **Kontos CK**, Adamopoulos PG, Scorilas A. A modified RNA-seq protocol uncovers the existence of novel alternatively spliced variants using Next-Generation Sequencing (Semiconductor Sequencing): the paradigm of carcinoembryonic antigen-related cell adhesion molecule 19 (*CEACAM19*). *Bioinformatics for Non-Coding RNAs*: 2014.
120. Adamopoulos PG, **Kontos CK**, Scorilas A. Discovery of novel splice variants of the human carcinoembryonic antigen-related cell adhesion molecule 19 (*CEACAM19*) gene in cancer and leukemic cell lines, using next-generation (semi-conductor) sequencing. *Int Soc Enz Meeting*: 2014.

121. **Kontos CK** and Scorilas A. The use of next generation sequencing for biomarker discovery. *Tumour biomarkers: From discovery to clinical applications*: 2014.
122. Adamopoulos PG, **Kontos CK**, Papageorgiou SG, Pappa V, Scorilas A. *KLKB1* mRNA overexpression possesses significant discriminatory value in chronic lymphocytic leukemia. *Tumour biomarkers: From discovery to clinical applications*: 2014.
123. Skourti E, Logotheti S, **Kontos CK**, Trougakos IP, Michalopoulos I, Scorilas A, Zoumpourlis V. The functional role of miR-200 family miRNAs and miR-205 in the progression of the mouse skin carcinogenesis through downregulating specific oncogenes. *Tumour biomarkers: From discovery to clinical applications*: 2014.
124. Papageorgiou S, **Kontos CK**, Foukas P, Panopoulou E, Economopoulou P, Kefala M, Ioannidou ED, Vasilatou D, Mpazani E, Panayiotides I, Scorilas A, Pappa V. Loss of BCL2L12 protein expression predicts relapse in patients with diffuse large B-cell lymphoma treated with rituximab plus conventional chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone), R-CHOP. *Proc EHA*: 2014.
125. **Kontos CK**, Daskalaki S, Fragoulis EG, Scorilas A. mRNA levels of the human gene encoding *L-DOPA* decarboxylase (DDC) are altered in colorectal adenocarcinoma cells after treatment with anticancer agents. *Cell cycle and natural products*: 2014.
126. Rapti SM, **Kontos CK**, Christodoulou S, Papadopoulos IN, Scorilas A. miR-34a, miR-96, and miR-182: Three miRNAs targeting apoptosis-related genes are novel molecular tissue biomarkers in colon cancer predicting unfavorable patient outcome. *Oncogenic Pathways and Antitumor Response*: 2014.
127. **Kontos CK**, Adamopoulos PG, Scorilas A. Identification of novel alternative splicing variants of *CEACAM19*, a new member of the carcinoembryonic antigen-related cell adhesion molecule (*CEACAM*) family, in human cancer cells, using next-generation sequencing. *Oncogenic Pathways and Antitumor Response*: 2014.
128. Ioannidou ED, Mpakou V, Vikentiou M, Konsta E, Kontsioti F, **Kontos CK**, Papageorgiou S, Atta M, Papanikolaou N, Bouchla A, Roubakis C, Dimitriadis G, Pappa V. Quantitative and qualitative analysis of regulatory T cells (Tregs) derived from the peripheral blood of chronic lymphocytic leukemia patients. *Proc ASH*: 2013.
129. Skourti E, **Kontos C**, Scorilas A, Zoumpourlis V. miR-200 family miRNAs and miR-3069 expression is significantly differentiated between early and late mouse skin carcinogenesis stages. *Proc Int Symp Mol Med*: 2013.
130. Alexopoulou DK, **Kontos CK**, Christodoulou S, Papadopoulos IN, Scorilas A. Kallikrein-related peptidase 11 (*KLK11*) mRNA expression predicts short-term relapse and poor overall survival in colorectal cancer patients. *Proc Int Symp Kallikr*: 2013.
131. Adamopoulos P, **Kontos CK**, Rapti SM, Christodoulou S, Papadopoulos IN, Scorilas A. Enhanced *miR224* transcription predicts short-term relapse and poor overall survival in colorectal adenocarcinoma patients. *Proc Int Symp Kallikr*: 2013.
132. Foteinou E, **Kontos CK**, Yiotakis AI, Yiotakis I, Scorilas A. Kallikrein-related peptidase 4 (*KLK4*) mRNA expression: an independent favorable prognosticator of head and neck squamous cell carcinoma patients' disease-free survival. *Proc Int Symp Kallikr*: 2013.
133. **Kontos CK**, Alexopoulou DK, Christodoulou S, Papadopoulos IN, Scorilas A. Kallikrein-related peptidase 6 (*KLK6*) mRNA expression: an independent unfavorable prognosticator in colon cancer. *Proc Int Symp Kallikr*: 2013.
134. **Kontos CK**, Rapti SM, Christodoulou S, Papadopoulos IN, Scorilas A. miR-34a overexpression is a strong indicator of unfavorable survival outcome in colon cancer patients. *Proc Int Symp Kallikr*: 2013.

135. Rapti SM, **Kontos CK**, Christodoulou S, Papadopoulos IN, Scorilas A. miR-96: A novel molecular tissue biomarker predicting unfavorable outcome in colorectal cancer patients. *Proc Int Symp Kallikr*: 2013.
136. Foteinou E, **Kontos CK**, Yiotakis AI, Yiotakis I, Scorilas A. Kallikrein-related peptidase 4 (*KLK4*) mRNA predicts short-term relapse in head and neck squamous cell carcinoma patients. *Ageing and Cancer*: 2013.
137. **Kontos CK**, Christodoulou MI, Fragoulis EG, Scorilas A. Quantification and study of the *L-DOPA* decarboxylase (*DDC*) mRNA expression in human colorectal adenocarcinoma cells treated with chemotherapeutic drugs. *Ageing and Cancer*: 2013.
138. **Kontos CK**, Daskalaki S, Talieri M, Scorilas A. Molecular profile of key apoptosis-related *BCL2*-family genes including *BCL2L12* in colorectal adenocarcinoma cells after treatment with chemotherapeutic agents. *Ageing and Cancer*: 2013.
139. Rapti SM, **Kontos CK**, Christodoulou S, Papadopoulos IN, Scorilas A. miR-34a, miR-96 and miR-182: novel molecular biomarkers with strong potential for the prediction of short-term relapse and overall survival in colorectal adenocarcinoma. *Ageing and Cancer*: 2013.
140. Skourti E, Logotheti S, Galtsidis S, Kritikos A, Xipolita M, **Kontos C**, Scorilas A, Trougakos I, Zoumpourlis V. Implication of miR-200 family miRNAs and miR-3069 in the progression of mouse skin carcinogenesis. *Ageing and Cancer*: 2013.
141. Kontsioti F, Foukas P, Papageorgiou S, Mpakou V, Kefala M, **Kontos C**, Ioannidou ED, Atta M, Bouchla A, Girkas K, Roubakis C, Panayiotides I, Dimitriadis G, Pappa V. Molecular and immunohistochemical analysis of cell cycle regulatory genes in diffuse large B-cell lymphomas. *Proc EHA*: 2013.
142. Gardikas N, Konsta E, Vikentiou M, Kapsimali V, **Kontos C**, Ioannidou ED, Oikonomopoulou C, Atta M, Papanikolaou N, Bouhla A, Papageorgiou S, Stamouli M, Dimitriadis G, Pappa V. Analysis of bone marrow CD34(+) subpopulations by flow cytometry in patients with myelodysplastic syndromes. *Proc EHA*: 2013.
143. Gkirkas K, Bakou V, Spathis A, Kottaridi C, Kontsioti F, **Kontos C**, Papageorgiou S, Bouhla A, Papanikolaou N, Atta M, Ioannidou E, Roubakis C, Stamouli M, Economopoulos T, Dimitriadis G, Pappa V. Analysis of apoptosis and mitochondrial cytochrome C-oxidase gene mutations in bone marrow cells of patients with myelodysplastic syndromes. *Proc Int Symp MDS*: 2013.
144. Kladi-Skandali A, **Kontos CK**, Tzovaras A, Talieri M, Missitzis I, Ardavanis A, Scorilas A. Quantitative expression analysis and study of *BCL2L12* and other members of the *BCL2* apoptosis-related gene family, as promising biomarkers for monitoring of prostate and colon cancer cellular response to chemotherapy. *Proc AACR*: 2013.
145. **Kontos CK**, Mavridis K, Scorilas A. Quantitative expression analysis and study of *BCL2L12* and other members of the *BCL2* apoptosis-related gene family, as promising biomarkers for monitoring of prostate and colon cancer cellular response to chemotherapy. *22nd ETRS Meeting*: 2012.
146. **Kontos CK**, Papadopoulos IN, Chantzis D, Scorilas A. Kallikrein-related peptidase 4 (*KLK4*) mRNA expression: a novel molecular tissue biomarker for the prediction of short-term relapse in colorectal adenocarcinoma. *Proc AACC*: 2012.
147. Karan-Djurasevic T, Palibrk V, Tosic N, Kostic T, Spasovski V, Nikcevic G, Srzentic S, Glumac I, Colovic M, Colovic N, Antic D, Mihaljevic B, Scorilas A, **Kontos C**, Pavlovic S. Expression of *BCL2L12* gene in chronic lymphocytic leukemia: association with clinical and molecular prognostic markers. *Proc EHA*: 2012.

148. **Kontos CK**, Thomadaki H, Mavridis K, Ardavanis A, Scorilas A. Identification and molecular cloning of novel splicing variants of *BCL2L12*, a new member of the *BCL2* family, and their expression analysis in breast, prostate, and colon cancer cells. *Proc AACR*: 2012.
149. **Kontos CK**, Pappa V, Vasilatou D, Pavlou MA, Kontsioti F, Papageorgiou SG, Tsiotra P, Economopoulou C, Bakou V, Papageorgiou E, Economopoulos T, Dervenoulas J. Let-7a, miR-17 and miR-20a expression levels in CD34+ bone marrow cells of patients with myelodysplastic syndromes (MDS) are associated with established prognostic factors, supporting their implication in the pathogenesis of the disease. *Proc ASH*: 2011.
150. **Kontos CK**, Chantzis D, Papadopoulos IN, Scorilas A. *KLK4* mRNA expression in colon cancer: a novel biomarker with significant prognostic value. *Proc Int Symp Kallikr*: 2011.
151. **Kontos CK**, Klettas D, Toutouzas K, Ageli C, Katsargyris A, Klonaris C, Scorilas A. Expression analysis of kallikrein-related peptidases in human carotid atherosclerotic lesions. *Proc Int Symp Kallikr*: 2011.
152. **Kontos C**, Papageorgiou S, Pappa V, Thomadaki H, Kontsioti F, Dervenoulas J, Papageorgiou E, Vasilatou D, Economopoulou C, Scorilas A. *BCL2L12*, a novel member of the *BCL2* family, is dramatically elevated in chronic lymphocytic leukemia (CLL) patients and constitutes an unfavorable biomarker in CLL, predicting poor overall survival, *Proc EHA*: 2011.
153. Vasilatou D, Pappa V, **Kontos CK**, Kontsioti F, Papageorgiou S, Tsigiotis P, Economopoulou C, Ioannidou E, Papageorgiou E, Dervenoulas I. Analysis of let-7a, miR-17 and miR-20a microRNA expression in CD34+ bone marrow cells of patients with myelodysplastic syndromes. *Proc Int Symp MDS*: 2011.
154. Vasilatou D, Pappa V, Kontsioti F, Papageorgiou S, **Kontos CK**, Tsiotra P, Economopoulou C, Bakou V, Papageorgiou E, Economopoulos T, Dervenoulas J. Analysis of let-7a and mir-17-5p micro-RNAs expression in patients with adult *de novo* myelodysplastic syndromes. *Proc ASH*: 2010.
155. **Kontos CK**, Chantzis D, Papadopoulos IN, Scorilas A. Quantitative expression analysis and prognostic significance of *KLK4* mRNA expression in colon cancer. *Proc Int Symp Kallikr*: 2009.
156. **Kontos CK**, Papadopoulos IN, Fragoulis EG, Scorilas A. mRNA quantitative analysis and study of the *L-DOPA* decarboxylase (*DDC*) gene in colon cancer. *Proc FEBS*: 2009.
157. Liakata E, **Kontos C**, Scorilas A, Maratou E, Kontsioti F, Rontogianni D, Papageorgiou S, Pappa V, Pectasides D, Harhalakis N, Economopoulos T, Psyrris A. Increased copy numbers of the *PI3KCA* gene may contribute to the pathogenesis of mantle cell lymphoma. *Proc FEBS*: 2008.
158. **Kontos CK**, Papadopoulos IN, Fragoulis EG, Scorilas A. Prognostic significance of *L-DOPA* decarboxylase (*DDC*) expression in colon cancer. *Proc FEBS*: 2008.
159. Papageorgiou S, Psyrris A, Liakata E, Scorilas A, Rontogianni D, **Kontos C**, Argiriou P, Pappa V, Harhalakis N, Pectasides D, Economopoulos T. *PIK3CA* as a molecular target in mantle cell lymphoma. *Proc ASCO*: 2008.
160. **Kontos CK**, Papadopoulos IN, Scorilas A. The novel apoptosis-related gene, *BCL2L12*, is an independent and favorable prognostic marker for colon cancer. *Proc AACR*: 2008.
161. **Kontos CK**, Thomadaki H, Florou D, Avgeris M, Korbakis D, Scorilas A. Quantitative mRNA expression analysis and study of *BCL2L12*, a novel member of the apoptosis-related genes, in cancer cell lines. *Proc Int Prot Soc*: 2007.
162. **Kontos CK**, Papadopoulos IN, Chantzis D, Scorilas A. The role of the novel apoptosis-related gene, *BCL2L12*, along colon cancer progression: a quantitative mRNA expression analysis. *Proc Int Prot Soc*: 2007.

163. Avgeris M, Mavridis K, Thomadaki H, **Kontos CK**, Avzoti K, Papaleksis P, Scorilas A. Expression analysis of the genes *KLK4* and *KLK15* in cancer cell lines. *Proc Int Symp Kallikr*: 2007.
164. Toubanaki DK, **Kontos CK**, Fragoulis EG, Christopoulos TK, Scorilas A. Development and validation of an RNA-based quantitative method for the determination of L-DOPA decarboxylase (*DDC*) at the mRNA level. *Proc Int Conf Instr Methods Anal*: 2007.
165. **Kontos CK**, Toubanaki DK, Fragoulis EG, Christopoulos TK, Scorilas A. Quantitative analysis and study of L-DOPA decarboxylase (*DDC*) in cancer cells lines using real-time and competitive RT-PCR assays. *Proc FEBS*: 2007.
166. **Kontos CK**, Papadopoulos IN, Chantzis D, Scorilas A. Expression analysis and prognostic significance of *BCL2L12*, a new member of the apoptosis-related genes, in colon cancer. *Proc AACR*: 2007.
167. **Kontos CK**. Expression analysis and prognostic significance of *BCL2L12*, a new member of the *BCL2* family of apoptosis-related genes, in nasopharyngeal carcinoma. *Proc Conf Head Neck Cancer*: 2007.
168. **Kontos CK**, Fragoulis EG, Scorilas A. Expression analysis of L-DOPA decarboxylase (*DDC*) in human cancer cell lines using RT-PCR and quantitative real-time PCR. *Proc FEBS*: 2006.

F4. Abstracts in Proceedings of National Conferences

1. Papatsirou M, Mavrogonatou E, Trougakos IP, Kletsas D, Scorilas A, **Kontos CK**. Circular RNA expression dynamics reveal time- and dose-dependent responses to ionizing radiation in triple-negative breast cancer cells. *Proc HSBMB*: 2025.
2. Kalogerini K, Athanasopoulou K, Adamopoulos PG, Ntanas-Stathopoulos I, Trougakos IP, Scorilas A, Terpos E, **Kontos CK**. Uncovering the alternatively spliced transcripts of the human gene family encoding the lysosomal associated membrane proteins (LAMPs) in multiple myeloma cell lines. *Proc HSBMB*: 2025.
3. Sotiropoulou CD, **Kontos CK**, Bouchla A, Chatziligeroudi T, Papageorgiou SG, Vitsioti A, Apostolopoulou C, Markaki I, Karamanou G, Karantanos T, Pappa V. *PPP1R15A* as a therapeutic target for chemoresistance overcoming in AML: An *in vitro* study. *Cong Hel Soc Haematol*: 2025.
4. Katsaraki K, Sideris DC, Scorilas A, **Kontos CK**. Uncovering the regulation of key signaling pathways by novel circular *BAX* transcripts, discovered *via* a targeted nanopore-sequencing approach. *Proc HSBMB*: 2024.
5. Papatsirou M, Ntanas-Stathopoulos I, Kletsas D, Scorilas A, Terpos E, **Kontos CK**. Exploring the Broad Circular RNA Landscape of Multiple Myeloma Cell Lines Using 3rd Generation Sequencing. *Proc HSBMB*: 2024.
6. Sotiropoulou CD, Pappa V, Scorilas A, Papageorgiou SG, **Kontos CK**. Integrating Next-Generation and 3rd-Generation Sequencing to Discover Circular RNAs of *BAX* and *BCL2L12* Genes in Acute Myeloid Leukemia. *Proc HSBMB*: 2024.
7. Katsaraki K, Sideris DC, Scorilas A, **Kontos CK**. Human miR-22-5p emerges as a significant regulator of the PI3K/AKT signaling pathway in breast cancer. *Proc HSBMB*: 2024.
8. **Kontos CK**, Karousi P, Papatsirou P, Sotiropoulou CD, Katsaraki K, Dimitriadou A, Sideris DC, Scorilas A. Unraveling unconventional biogenesis of human circular RNAs (circRNAs). *Proc HSBMB*: 2023.

9. Karousi P, Samiotaki M, Makridakis M, Zoidakis J, Sideris DC, Scorilas A, Carell T, **Kontos CK**. Exploring the regulatory impact of 3'-tRF-Cys^{GCA} on gene expression in HEK-293 cells. *Proc HSBMB*: 2023.
10. Papatsirou M, **Kontos CK**, Ntanas-Stathopoulos I, Malandrakis P, Theodorakakou F, Liacos CI, Mavrianou-Koutsoukou N, Fotiou D, Migkou M, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Scorilas A, Terpos E. The *circCCT3* circular RNA is overexpressed in CD138+ bone marrow cells of multiple myeloma patients and constitutes a favorable prognostic factor of the disease, independently of the R-ISS staging. *Cong Hel Soc Haematol*: 2023.
11. **Kontos CK**. The functional role and clinical significance of non-coding RNAs in hematological malignancies. *Clin Chem - Clin Biochem Conf*: 2023.
12. Avgeris M, Papadimitriou MA, Pilala KM, Panoutsopoulou K, Levis P, Kotronopoulos G, Kanaki Z, Loules G, Zamanakou M, **Kontos CK**, Sideris DC, Stravodimos K, Klinakis A, Scorilas A. Cell-free DNA in modern prognosis of bladder cancer. *Clin Chem - Clin Biochem Conf*: 2023.
13. Papadaki C, Vourka A, Lepenou S, Karousi P, **Kontos CK**, Karaouzas I, Parmakelis A. Environmental DNA as a tool for the assessment of the biodiversity of invertebrates in inland water ecosystems of Greece. *Cong Hel Ecol Soc*: 2023.
14. Karousi P, **Kontos CK**^{*}, Kostakis IK, Skaltsounis AL, Scorilas A^{*}. Treatment of triple-negative breast cancer cells with oleuropein and oleocanthal significantly alters the gene expression profile. *Cong Hel Soc Biol Sci*: 2023.
15. Papatsirou P, Kletsas D, Scorilas A, **Kontos CK**. Identification of alternatively spliced, circular transcripts (circRNAs) of the *PRMT1* gene in breast cancer cell lines, using targeted nanopore sequencing. *Proc HSBMB*: 2022.
16. Sotiropoulou CD, Kostopoulou I, Scorilas A, **Kontos CK**. The mRNA expression of apoptosis- and autophagy-related genes in prostate cancer cells is modulated upon treatment with bortezomib and carfilzomib. *Proc HSBMB*: 2022.
17. Karousi P, Sideris DC, Scorilas A, **Kontos CK**. Overexpression of the tRNA derivative 3'-tRF-Cys^{GCA} in HEK-293 cells leads to downregulation of epigenetic regulators. *Proc HSBMB*: 2022.
18. Katsaraki K, Szot ND, Scorilas A, **Kontos CK**. Novel circular transcripts (circRNAs) of the human *BAX* gene discovered using targeted third-generation sequencing, based on the nanopore technology. *Proc HSBMB*: 2022.
19. Gianniou DD, Papanagnou ED, Evangelakou Z, **Kontos CK**, Manola MS, Scorilas A, Kostakis IK, Skaltsounis AL, Trougakos IP. The emergence of Oleuropein-based compounds as potent anticancer agents. *Proc HSBMB*: 2022.
20. Karousi P, Machairas N, Xenou K, Papatsirou M, Scorilas A, **Kontos CK**. Identification of novel circular RNAs of *BCL2L12* gene in multiple myeloma cells via targeted 3rd generation nanopore sequencing and quantitative determination with nested real-time qPCR methodology. *Cong Hel Soc Haematol*: 2022.
21. Papatsirou M, **Kontos CK**, Ntanas-Stathopoulos I, Karousi P, Malandrakis P, Theodorakakou F, Liacos CI, Liosi AA, Kalioraki MA, Mavrianou-Koutsoukou N, Fotiou D, Migkou M, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Scorilas A, Terpos E. The ciRS-7 circular RNA displays differential expression in CD138+ cells of patients with plasma cells dyscrasias and constitutes a potential biomarker of unfavorable prognosis in multiple myeloma. *Cong Hel Soc Haematol*: 2022.
22. Sotiropoulou C, Xenou K, Karousi P, Machairas N, Pappa V, Scorilas A, Papageorgiou SG, **Kontos CK**. Identification of novel circular RNAs (circRNAs) of the apoptosis-related *BCL2L12* gene using targeted 3rd generation nanopore sequencing in human acute myeloid leukemia and myelodysplastic syndrome cells. *Cong Hel Soc Haematol*: 2022.

23. Artemaki PI, Scorilas A, **Kontos CK**. Unraveling BCL2-ovarian killer (*BOK*) alternative splicing pattern in human cancer cell lines, using targeted nanopore sequencing. *Proc HSBMB*: 2021.
24. Artemaki PI, Karousi P, Trougakos IP, Scorilas A, **Kontos CK**. Novel protein-coding and non-coding transcripts of BCL2-ovarian killer (*BOK*) support its multifaceted role in human cells. *Proc HSBMB*: 2021.
25. Karousi P, Sideris DC, Scorilas A, **Kontos CK**. Targeted long-read sequencing reveals a wide variety of circular *BCL2L12* transcripts and novel aspects of circular RNA (circRNA) biology. *Proc HSBMB*: 2021.
26. Papatsirou P, Katsaraki K, **Kontos CK**, Kletsas D, Scorilas A. Unraveling the intricacy of the breast cancer transcriptome: novel circular RNAs of the *PRMT1* gene display a wide range of splicing events. *Proc HSBMB*: 2021.
27. Skeparnias I, Kyriakopoulos G, Grafanaki K, Alexopoulos P, Dougenis D, Scorilas A, **Kontos CK**, Stathopoulos C. Contribution of miRNA, tRNA and tRF molecules in deregulation of signaling and translation in lung cancer. *Ann Med Cong*: 2021.
28. Katsaraki K, Karousi P, Adamopoulos PG, Papageorgiou SG, Pappa V, Scorilas A **Kontos CK**. Development of a new molecular methodology for the quantification of tRNA-derived RNA fragments (tRFs) and correlation of the levels of two tRFs with the survival of chronic lymphocytic leukemia patients. *Cong Hel Soc Haematol*: 2020.
29. Adamopoulos PG, **Kontos CK**, Tsiakanikas P, Diamantopoulos MA, Scorilas A. Identification and Molecular Cloning of Novel Kallikrein Gene Isoforms and their Targeting Non-Coding RNAs in Cancer Cells. *Proc HSBMB*: 2019.
30. Papanota AM, Artemaki PI, **Kontos CK**, Liacos C, Karousi P, Patseas D, Papadimitriou MA, Eleutherakis-Papaiakevou E, Avgeris M, Kanellias N, Bagratuni T, Roussou M, Dialoupi I, Kastitis E, Gavriatopoulou M, Scorilas A, Dimopoulos MA, Terpos E. The clinical significance of a new group of microRNA molecules in multiple myeloma. *Cong Hel Soc Haematol*: 2019.
31. Papanota AM, Karousi P, **Kontos CK**, Liacos C, Artemaki PI, Patseas D, Liosi AA, Mavrianou-Koutsoukou N, Kalioraki MA, Fotiou D, Ntanasis-Stathopoulos I, Migkou M, Malandrakis P, Gavriatopoulou M, Kastitis E, Scorilas A, Dimopoulos MA, Terpos E. Three novel tRNA-derived RNA fragments can effectively distinguish symptomatic from asymptomatic multiple myeloma. *Cong Hel Soc Haematol*: 2019.
32. **Kontos CK**, Adamopoulos PG, Scorilas A. Molecular characterization, genomic structure, and expression analysis of the *CATLI* (*CPTIC*) gene, a third member of the human carnitine acyltransferase family. *Proc HSBMB*: 2018.
33. Artemaki PI, Adamopoulos PG, Scorilas A, **Kontos CK**. *In silico* identification and experimental validation of novel transcripts of the members of the apoptosis-related BCL2 family in human cell lines. *Proc HSBMB*: 2018.
34. Kalioraki MA, Liosi AA, Sklirou AD, Cheimonidi MC, **Kontos CK**, Scorilas A, Trougakos IP. High mRNA expression of the molecular chaperone Clusterin (CLU) and heat-shock protein beta-3 (HSPB3) is associated with colorectal cancer recurrence. *Proc HSBMB*: 2018.
35. Sklirou AD, Kamouza E, Gianniou DD, Cheimonidi MC, **Kontos CK**, Scorilas A, Trougakos IP. *HSPB2* gene transcription is downregulated in breast cancer, while its upregulation is associated with breast cancer patients' relapse. *Proc HSBMB*: 2018.
36. Tsiakanikas P, Adamopoulos PG, **Kontos CK**, Panagiotou A, Vassilacopoulou D, Scorilas A. Identification of novel transcripts of human *L-DOPA* decarboxylase (*DDC*) in human cancer cells, using next-generation sequencing. *Proc HSBMB*: 2018.
37. Papageorgiou SG, Kamouza E, Karousi P, **Kontos CK**, Bouchla A, Bazani E, Pavlidis G, Glezou E, Scorilas A, Pappa V. Study of the combinatorial prognostic significance of the expression of

HIF1A mRNA and three microRNAs regulating its expression in chronic lymphocytic leukemia patients. *Cong Hel Soc Haematol*: 2018.

38. Diamantopoulos MA, **Kontos CK**, Papageorgiou SG, Bazani E, Pappa V, Scorilas A. High microRNA-155-5p expression levels in peripheral blood mononuclear cells of chronic lymphocytic leukemia patients is associated with poor overall survival. *Proc HSBMB*: 2017.
39. Adamopoulos PG, **Kontos CK**, Tsiakanikas P, Scorilas A. Identification and molecular cloning of novel transcripts of human kallikrein-related peptidases 5, 6, 7, 8 and 9 (*KLK5 – KLK9*) in human cancer cells, using Next-Generation Sequencing. *Proc HSBMB*: 2017.
40. Grafanaki K, Korfiati A, **Kontos C**, Theofilatos K, Mavroudi S, Skeparnias I, Kyriakopoulos G, Papaioannou D, Scorilas A, Stathopoulos C, Drainas D. Transcriptomic analysis on human keratinocytes reveals the anticancer activity of the novel synthetic retinoid RASP. *Proc HSBMB*: 2017.
41. Papageorgiou SG, **Kontos CK**, Bouchla A, Tsiampalis T, Vyniou AN, Symeonidis A, Galanopoulos A, Kotsianidis I, Pappa V, Hellenic (Greek) MDS Study Group. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes (MDS) treated with 5-Azacitidine. *Cong Hel Soc Haematol*: 2017.
42. Papageorgiou SG, **Kontos CK**, Bazani E, Tsiampalis T, Vyniou AN, Symeonidis A, Galanopoulos A, Kotsianidis I, Pappa V, Hellenic (Greek) MDS Study Group. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-Azacytidine: A retrospective study of the Hellenic (Greek) MDS Study Group. *Cong Hel Soc Haematol*: 2017.
43. Tsakiraki Z, Papageorgiou S, **Kontos CK**, Spathis A, Bouchla A, Bazani E, Glezou E, Stavroulaki G, Karakitsos P, Panayiotides I, Pappa V, Foukas P. The immune microenvironment as a predictive marker of response of high-risk MDS patients to treatment with 5-Azacitidine. *Cong Hel Soc Haematol*: 2017.
44. Papageorgiou SG, Diamantopoulos IMA, **Kontos CK**, Vasilatou D, Bouchla A, Glezou E, Stavroulaki G, Bazani E, Scorilas A, Dimitriadis G, Pappa V. High expression of miR-155-5p constitutes a novel, independent molecular biomarker of unfavorable prognosis in chronic lymphocytic leukemia patients. *Cong Hel Soc Haematol*: 2017.
45. Papageorgiou SG, Tsiakanikas P, **Kontos CK**, Vasilatou D, Glezou E, Stavroulaki G, Bouchla A, Gkontopoulos K, Bazani E, Scorilas A, Dimitriadis G, Pappa V. Low expression of miR-20b-5p constitutes a novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia patients. *Cong Hel Soc Haematol*: 2017.
46. Galanopoulos A, **Kontos CK**, Symeonidis A, Kotsianidis I, Kourakli A, Pappa V, Tsiambalis T, Pouli A, Panayiotidis P, Roussou P, Karakatsanis S, Zafeiropoulou K, Dimou M, Vassilakopoulos T, Vardi A, Tsokanas D, Drakos G, Hatzimichael E, Megalakaki A, Repousis P, Kotsopoulou M, Solomou E, Kaiafa GD, Papoutselis MK, Sioni A, Charchalakis N, Bouronikou E, Vassilopoulos G, Lazaris V, Spiliotopoulou M, Diamantopoulos PT, Kontopidou F, Topouzoglou Z, Kalyva S, Papadaki HA, Hatzitolios AI, Anagnostopoulos A, Anagnostopoulos NI, Viniou NA. Prognosis of patients with low-risk Myelodysplastic Syndrome, without isolated del(5q), after failure of response to treatment with erythropoiesis-stimulating agents: A multicenter study by the Hellenic MDS Study Group. *Cong Hel Soc Haematol*: 2017.
47. Galanopoulos A, **Kontos CK**, Viniou NA, Kotsianidis I, Pappa V, Kourakli A, Tsiambalis T, Pouli A, Panayiotidis P, Roussou P, Karakatsanis S, Zafeiropoulou K, Dimou M, Vassilakopoulos T, Vardi A, Tsokanas D, Drakos G, Hatzimichael E, Megalakaki A, Repousis P, Kotsopoulou M, Solomou E, Kaiafa GD, Papoutselis MK, Sioni A, Charchalakis N, Bouronikou E, Vassilopoulos G, Lazaris V, Spiliotopoulou M, Diamantopoulos PT, Kontopidou F, Topouzoglou Z, Kalyva S, Papadaki HA, Hatzitolios AI, Anagnostopoulos A, Anagnostopoulos NI, Symeonidis A.

Epidemiologic features of patients with Myelodysplastic Syndromes in Greek population: A multicenter study by the Hellenic MDS Study Group. *Cong Hel Soc Haematol*: 2017.

48. Panagiotou A, Tsiakanikas P, Adamopoulos P, **Kontos C**, Scorilas A. Discovery of novel alternatively spliced variants of the *L-DOPA* decarboxylase (*DDC*) gene and their expression analysis in human cancer cells. *Cong Hel Soc Biol Sci*: 2017.
49. Diamantopoulos M, Kerimis D, **Kontos C**, Papadopoulos I, Scorilas A. High miR-16 expression is a novel, promising molecular biomarker of poor prognosis in colorectal adenocarcinoma. *Cong Hel Soc Biol Sci*: 2017.
50. **Kontos CK**, Adamopoulos PG, Diamantopoulos IMA, Scorilas A. Discovery and molecular characterization of novel transcripts of kallikrein-related peptidases 5, 6, 7, 8, and 9 (*KLK5* – *KLK9*) in human cancer cells, using next-generation sequencing. *Proc HSBMB*: 2016.
51. Diamantopoulos IMA, Adamopoulos PG, **Kontos CK**, Scorilas A. Discovery, molecular cloning and expression analysis of novel alternative splicing variants of the *AP2A1* gene with the use of next-generation sequencing. *Proc HSBMB*: 2016.
52. Michailidou KA, Apostolopoulou XK, Lagoumtzis TN, Lappa IA, Avgeris M, Giaouris E, **Kontos CK**. Development and application of a PCR assay for sensitive and specific detection of food contamination with *Listeria monocytogenes*, *Salmonella spp.* and *Escherichia coli*. *Proc HSBMB*: 2016.
53. Tsigara EG, Kakaridi M, Karantonis H, **Kontos CK**. Extracts from Limnio grape skin trigger apoptosis in breast cancer MCF-7 cells by activating the intrinsic apoptotic pathway. *Proc HSBMB*: 2016.
54. Tsigara MG, Markopoulou I, **Kontos CK**, Karantonis H. Assessment of the antioxidant activity and proapoptotic effect of Moscato Alexandria grape seed extracts on human gastric cancer cells. *Proc HSBMB*: 2016.
55. Delladetsima K, Karra F, Brokos N, Polemikos G, **Kontos C**, Giaouris E. Presence of important virulence genes in *Staphylococcus aureus* cheese isolates and *in vitro* investigation of their biofilm forming abilities under pH or water activity stresses. *Proc HSBMB*: 2016.
56. Galanopoulos A, **Kontos CK**, Viniou NA, Kotsianidis I, Pappa V, Kourakli A, Pouli A, Panayiotidis P, Roussou P, Zafeiropoulou K, Karakatsanis S, Dimou M, Vardi A, Vassilakopoulos T, Tsokanas D, Hatzimichael E, Megalakaki A, Kaiafa GD, Papoutselis MK, Sioni A, Charchalakakis N, Bouronikou E, Vassilopoulos G, Lazaris V, Spiliotopoulou M, Diamantopoulos PT, Kontopidou F, Topouzoglou Z, Kalyva S, Papadaki HA, Hatzitolios AI, Anagnostopoulos A, Briasoulis E, Anagnostopoulos NI, Symeonidis AS. Validation of the Revised International Prognostic Scoring System in 2582 patients with myelodysplastic syndrome: a multicenter study by the Hellenic MDS Study Group. *Cong Hel Soc Haematol*: 2016.
57. Papageorgiou SG, **Kontos CK**, Diamantopoulos IMA, Vasilatou D, Glezou E, Stavroulaki G, Gkontopoulos K, Bazani E, Scorilas A, Dimitriadis G, Pappa V. mRNA overexpression of the hypoxia inducible factor 1 alpha subunit gene (*HIF1A*) is a novel independent molecular biomarker of unfavorable prognosis in patients with B-cell chronic lymphocytic leukemia. *Cong Hel Soc Haematol*: 2016.
58. Papageorgiou SG, **Kontos CK**, Vasilatou D, Stavroulaki G, Glezou E, Gkontopoulos K, Bazani E, Dimitriadis G, Pappa V. Investigation of the prognostic value of the established prognostic systems IPI, R-IPI and NCCN-IPI, in patients with diffuse large B-cell lymphoma (DLBCL). *Cong Hel Soc Haematol*: 2016.
59. Papageorgiou SG, **Kontos CK**, Bazani E, Vasilatou D, Glezou E, Stavroulaki G, Dimitriadis G, Pappa V. Investigation of the prognostic value of the presence of monoclonal paraprotein in the serum of patients with diffuse large B-cell lymphoma (DLBCL). *Cong Hel Soc Haematol*: 2016.

60. Kerimis D, **Kontos CK**, Tsiakanikas P, Diamantopoulos IM, Christodoulou S, Papadopoulos IN, Scorilas A. The microRNAs miR-16 and miR-28-5-p constitute novel potential molecular biomarkers of unfavorable prognosis in colorectal adenocarcinoma. *Clin Chem - Clin Biochem Conf*: 2016.
61. Lappa IA, Giaouris E, **Kontos C**. Development of a low-cost, highly specific and sensitive PCR-based methodology for the detection of the pathogenic *Escherichia coli* O157:H7 (O157) strain in widely consumed foods. *Cong Hel Soc Biol Sci*: 2016.
62. Apostolopoulou X, Tsigara E, Tsigara M, Giaouris E, **Kontos C**. Detection of bacteria of the *Salmonella* genus (*Salmonella* spp.) in widely consumed foods with a novel, highly sensitive, *in-house* developed PCR methodology. *Cong Hel Soc Biol Sci*: 2016.
63. Michailidou K, Lagoumtzis T, Avgeris M, Giaouris E, **Kontos C**. Development of a sensitive PCR-based methodology for the detection of *Listeria monocytogenes* in widely consumed foods. *Cong Hel Soc Biol Sci*: 2016.
64. Tsigara E, Lappa IA, Kakaridi M, Karantonis H, **Kontos C**. Study of apoptosis induction in breast cancer cells treated with extracts from Limnio's grape skin. *Cong Hel Soc Biol Sci*: 2016.
65. Tsigara M, Banta C, Markopoulou I, **Kontos C**, Karantonis H. *in vitro* study of the antioxidant and anticancer activity of seed extracts from Moscato Alexandria's and Limnio's grapes on gastric adenocarcinoma cells. *Cong Hel Soc Biol Sci*: 2016.
66. Depastas SC, Mpouzelos B, Diamantopoulos IM, **Kontos C**, Karantonis H. Study of the antioxidant and cytotoxic activity of seed extracts from *Chenopodium quinoa* (Quinoa) on prostate cancer cells. *Cong Hel Soc Biol Sci*: 2016.
67. Brokos N, Polemikos G, Delladetsima K, Karra F, **Kontos C**, Giaouris E. Effect of sodium chloride and glucose on biofilm formation by *Staphylococcus aureus* strains isolated from cheeses and study of the presence of important virulence genes. *Cong Hel Soc Biol Sci*: 2016.
68. Diamantopoulos IM, Adamopoulos P, **Kontos C**, Scorilas A. Discovery, cloning and expression analysis of novel alternative splicing variants of the *AP2A1* gene in human cancer cell lines. *Cong Hel Soc Biol Sci*: 2016.
69. Bakou V, Ioannidou E, Konsta E, Spathis A, Vikentiou M, Kontsioti F, **Kontos C**, Vasilatou D, Mpouchla A, Gontopoulos K, Roubakis C, Stavroulaki G, Papanikolaou N, Atta M Papageorgiou S, Mpazani E, Economopoulou C, Kokkori S, Kyriakou E, Dimitriadis G, Karakitsos P, Pappa V. Qualitative analysis of regulatory T cells (Tregs) in the peripheral blood of patients with B cell chronic lymphocytic leukemia. *Cong Hel Soc Haematol*: 2015.
70. Ioannidou E, Vikentiou M, Konsta E, Kapsimalli V, Bakou V, Kontsioti F, **Kontos C**, Vasilatou D, Mpouchla A, Gontopoulos K, Roubakis C, Stavroulaki G, Papageorgiou S, Mpazani E, Economopoulou C, Kokkori S, Kyriakou E, Dimitriadis G, Pappa V. Flow cytometry analysis of regulatory T cells (Tregs) in patients with B cell chronic lymphocytic leukemia (B-CLL). *Cong Hel Soc Haematol*: 2015.
71. Gardikas N, Vikentiou M, Konsta E, Kapsimalli V, **Kontos C**, Ioannidou E, Economopoulou C, Mpouchla A, Roubakis C, Vasilatou D, Papageorgiou S, Dimitriadis G, Pappa V. Flow cytometry analysis of maturation of CD34(+) hematologic stem cell subpopulations in bone marrow of patients with myelodysplastic syndrome. *Cong Hel Soc Haematol*: 2015.
72. Adamopoulos PG, **Kontos CK**, Tsiakanikas P, Scorilas A. Discovery of novel BCL2-like 12 (*BCL2L12*) transcripts in cancer cells, using next-generation sequencing. *Proc HSBMB*: 2015.
73. Anastasakis D, **Kontos C**, Grafanaki K, Marchand A, Skeparnias I, Kourmoutou GG, Kostopoulou ON, Alexopoulos P, Dougenis D, Drainas D, Jossinet F, Kalpaxis DL, Scorilas A, Stathopoulos C. The transcriptomic profile of tRNAs, tRFs, miRNAs and their related genes

suggests modulation of essential translation factors which promote elevated protein synthesis in Non Small Cell Lung Cancer. *Proc HSBMB*: 2015.

74. Grafanaki K, Anastasakis D, **Kontos C**, Magoulas G, Papaioannou D, Scorilas A, Drinas D. The retinoid-polyamine conjugate RASP exhibits anti-tumour activity through effects on cell cycle regulation. *Proc HSBMB*: 2015.
75. Anastasakis D, Grafanaki K, **Kontos C**, Skeparnias I, Apostolidi M, Konstantinidou P, Alexopoulos P, Gioutlakis A, Kostopoulou O, Dougenis D, Kalpaxis D, Drinas D, Moschonas N, Scorilas A, Stathopoulos C. Monitoring the expression dynamics of networks regulating the role of tRNA molecules in gene expression, signaling and translation in lung cancer. *Cong Hel Soc Biol Sci*: 2015.
76. Tsiakanikas P, **Kontos C**, Adamopoulos P, Scorilas A. Discovery of novel alternative splicing variants of the apoptosis-related *BCL2L12* gene and their expression analysis in human cancer cell lines. *Cong Hel Soc Biol Sci*: 2015.
77. Christodoulou S, **Kontos CK**, Alexopoulou DK, Scorilas A, Papadopoulos IN. *KLK11* mRNA expression: A novel biomarker in colorectal adenocarcinoma, predicting poor disease-free and overall survival. *Proc Nat Conf Surg Oncol*: 2014.
78. Anastasakis D, Grafanaki K, **Kontos C**, Skeparnias I, Apostolidi M, Konstantinidou P, Alexopoulos P, Gioutlakis A, Dougenis D, Drinas D, Moschonas NK, Scorilas A, Stathopoulos C. Monitoring the expression dynamics of networks controlling tRNA expression, signaling and translation in lung cancer. *Proc HSBMB*: 2014.
79. Grafanaki K, Anastasakis D, Fakiolas S, Magoulas G, Malavaki CJ, **Kontos C**, Scorilas A, Karamanos NK, Papaioannou D, Drinas D. Functional genomic analysis of a novel retinoid-polyamine conjugate exhibiting anti-inflammatory and anti-cancer properties. *Proc HSBMB*: 2014.
80. Papageorgiou S, Foukas P, **Kontos C**, Panopoulou E, Kefala M, Ioannidou ED, Bazani E, Economopoulou C, Vasilatou D, Panayiotides I, Scorilas A, Pappa V. Increased expression of the *BCL2L12* protein is an independent prognostic factor and predicts better overall survival in patients with diffuse large B-cell lymphoma in the Rituximab era. *Cong Hel Soc Haematol*: 2014.
81. Adamopoulos PG, **Kontos CK**, Papageorgiou S, Pappa V, Scorilas A. High mRNA expression of the *KLKB1* gene is associated with chronic lymphocytic leukemia. *Cong Hel Soc Haematol*: 2014.
82. Papageorgiou S, Vasilatou A, **Kontos CK**, Bazani E, Ioannidou ED, Economopoulou C, Atta M, Roubakis C, Tsirigotis P, Dimitriadis G, Pappa V. me. *Cong Hel Soc Haematol*: 2014. 5-Azacytidine in the treatment of high risk myelodysplastic syndromes. Experience of a single center. *Cong Hel Soc Haematol*: 2014.
83. Gardikas N, Vikentiou M, Konsta E, Kapsimalli V, **Kontos C**, Ioannidou E, Economopoulou C, Roubakis C, Vasilatou A, Papageorgiou S, Dimitriadis G, Pappa V. Flow cytometry analysis of different stages of maturation of CD34(+) hematologic stem cell subpopulations in bone marrow of patients with myelodysplastic syndrome. *Cong Hel Soc Haematol*: 2014.
84. Adamopoulos PG, **Kontos CK**, Rapti SM, Christodoulou S, Papadopoulos IN, Scorilas A. Elevated microRNA-224 (miR-224) levels in cancerous tissue predict short-term relapse and poor overall survival in colorectal adenocarcinoma. *Proc Nat Conf Surg Oncol*: 2013.
85. Rapti SM, **Kontos CK**, Christodoulou S, Papadopoulos IN, Scorilas A. microRNA-34, microRNA-96, and microRNA-182: three novel molecular tissue biomarkers with strong unfavorable prognostic significance in colorectal adenocarcinoma patients. *Proc Nat Conf Surg Oncol*: 2013.

86. Christodoulou S, **Kontos CK**, Alexopoulou DK, Scorilas A, Papadopoulos IN. Overexpression of Kallikrein-related peptidase 6 (*KLK6*) mRNA constitutes an independent unfavorable prognosticator in colon cancer. *Proc Nat Conf Surg Oncol*: 2013.
87. Adamopoulos PG, **Kontos CK**, Alexopoulou DK, Rapti SM, Papadopoulos IN, Scorilas A. Expression of miR-224, a novel molecular tissue biomarker predicting short-term relapse and poor overall survival in colorectal adenocarcinoma patients, is negatively correlated with mRNA levels of kallikrein-related peptidases 6 and 10. *Proc HSBMB*: 2013.
88. Rapti SM, **Kontos CK**, Christodoulou S, Papadopoulos IN, Scorilas A. MiR-200 family miR-182 constitutes a novel molecular tissue biomarker predicting unfavorable outcome in colorectal cancer patients. *Proc HSBMB*: 2013.
89. Skourti E, Xipolita M, **Kontos C**, Scorilas A, Christodoulou G, Logotheti S, Zoumpourlis V. MiR-200 family miRNAs significant downregulation and miR-3069 overexpression is observed in the late mouse skin carcinogenesis stages. *Proc HSBMB*: 2013.
90. Gardikas N, Konsta E, Vikentiou M, Kapsimalli V, **Kontos CK**, Ioannidou E, Economopoulou C, Bouchla A, Atta M, Papanikolaou N, Roubakis C, Papageorgiou S, Stamouli M, Dimitriadis G, Pappa V. Flow cytometry analysis of bone marrow CD34(+) subpopulations in patients with myelodysplastic syndrome. *Cong Hel Soc Haematol*: 2013.
91. Kontsioti F, Foukas P, Papageorgiou S, Bakou V, Kefala M, **Kontos C**, Ioannidou E, Atta M, Bouchla A, Papanikolaou N, Roubakis C, Panayiotides I, Dimitriadis G, Pappa V. Molecular and immunohistochemical study of cell cycle regulatory genes in diffuse large B-cell non-Hodgkin lymphomas. *Cong Hel Soc Haematol*: 2013.
92. Girkas K, Bakou V, Spathis A, Kottaridi C, Kontsioti F, **Kontos C**, Papageorgiou S, Bouchla A, Atta M, Papanikolaou N, Roubakis C, Karakitsos P, Dimitriadis G, Pappa V. Investigation of the mitochondrial cytochrome C oxidase gene mutations and apoptosis in myelodysplastic syndromes. *Cong Hel Soc Haematol*: 2013.
93. Adamopoulos P, **Kontos CK**, Papadopoulos IN, Ardavanis A, Scorilas A. Expression analysis and study of splice variants of the novel apoptosis-related gene *BCL2L12* in gastrointestinal cancer cells and tissues. *Cong Hel Soc Biol Sci*: 2013.
94. Kefala M, Papageorgiou S, Economopoulou P, **Kontos CK**, Pappa V, Patsouris E, Panayiotides I, Foukas P. Expression analysis of DNA damage response molecules in myelodysplastic syndromes. *Cong Hel Soc Haematol*: 2012.
95. Gardikas N, Konsta E, Vikentiou M, Papageorgiou S, **Kontos CK**, Ioannidou E, Pappa V, Tsirigotis P, Kapsimalli V, Dervenoulas J. Determination of hematological stem cell subpopulations in the bone marrow of patients with myelodysplastic syndrome (MDS), using flow cytometry. *Cong Hel Soc Haematol*: 2012.
96. Vasilatou D, Pappa V, **Kontos CK**, Pavlou MA, Kontsioti F, Papageorgiou S, Tsiotra P, Bakou V, Economopoulou C, Tsirigotis P, Bouchla A, Papageorgiou E, Dervenoulas J. Expression analysis of let-7a, miR-17 and miR-20a microRNAs in CD34+ bone marrow cells of patients with myelodysplastic syndrome. *Cong Hel Soc Haematol*: 2011.
97. Gardikas N, Konsta E, Vikentiou M, Pappa V, **Kontos CK**, Girkas E, Ioannidou E, Economopoulou C, Tsirigotis P, Kapsimalli V, Dervenoulas J. Study of apoptosis in CD34+ bone marrow cell subpopulations of patients with myelodysplastic syndromes (MDS). *Cong Hel Soc Haematol*: 2011.
98. **Kontos CK**, Bantounas I, Siakouli D, Pintzas A. The role of miR-21 in oncogenic signaling and epithelial-mesenchymal transition (EMT) in colorectal cancer. *Proc HSBMB*: 2011.
99. Thomadaki H, Adamopoulou M, **Kontos C**, Papaleksis P, Chaidopoulos D, Kalkani E, Scorilas A. Determination and study of the amplification of the *PIK3CA* gene encoding

phosphatidylinositol 3-kinase catalytic subunit- α in cervical tumors. *Tumor Mark & Targ Ther Cong*: 2010.

100. Papaleksis P, **Kontos C**, Christopoulos P, Papadias K, Anagnou N, Kreatsas G, Scorilas A. Expression analysis of phosphatidylinositol 3'-kinase catalytic subunit alpha (*PIK3CA*) gene expression in tumors of the female reproductive system. *Clin Chem - Clin Biochem Conf*: 2010.
101. Papaleksis P, Christopoulos P, **Kontos C**, Papadias K, Anagnou N, Kreatsas G, Scorilas A. Expression analysis of *KLK15* gene expression in tumors of the female reproductive system. *Ann Med Cong*: 2010.
102. Papageorgiou S, Psyrri A, Liakata E, Rontogianni D, Argyriou P, Kontsioti F, Economopoulou C, Maratou E, **Kontos C**, Economopoulou P, Pappa V, Scorilas A, Papageorgiou E, Harhalakis N, Pectasides D, Economopoulos T. PIK3/AKT pathway activation is independent of PTEN inactivation in mantle cell lymphoma and may be associated with increased PIK3CA gene copy number. *Cong Hel Soc Haematol*: 2007
103. **Kontos C**, Papadopoulos I, Chantzis D, Scorilas A. mRNA quantitative analysis and study of the *BCL2L12*, a new member of the apoptosis-related genes, in colon cancer. *Biosc Cong*: 2007.